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 This thesis is comprised of three projects that are driven by a common theme, which is 
the use of computational tools in aiding molecular probe and drug design. In the first project, the 
feasibility of using molecular docking and scoring to estimate binding affinity for small 
molecules labelled covalently with fluorophores was tested using several proof-of-concept 
experiments. The high-throughput nature of computational screening applications such as 
Hierarchical Virtual Ligand Screening (HierVLS) necessitate that, in order to screen these 
labelled compounds, there must be an automated way to generate the associated structures 
virtually from large databases of base compounds and fluorophores. A script was developed in 
MOE software using scientific vector language (SVL) that could identify key reactive functional 
groups in both reactive fluorophores and target base compounds, and create the appropriate 
labelled structures for screening. The final fluorescence-labelled database numbers 14,862 
compounds, each tagged with the ATTO680 fluorophore. 
 In a subsequent project, the fluorescence-tagged library was screened against carbonic 
anhydrase 9 (CAIX), a protein implicated as a biomarker in several cancer types. This screening 
was accompanied by the screening of a validation set of known CAIX ligands and appropriately 
chosen decoys. The best scoring protocol according to our analyses was that which used 
principal components analysis. Ten of the top scoring candidates are suggested for future testing 
as probe candidates. CAIX binding sites were compared with equivalent residues in the 
sequences of 24 other CA isoforms to identify sites that might confer CAIX specificity, and the 
top scoring ligands were ranked according to this scheme. 
 
II 
 Lastly, experimental characterization was performed on three previously identified 
potential ligands for a cancer-related receptor tyrosine kinase, EphB4. Two in vitro assay formats 
were used: a homogenous time-resolved fluorescence assay and an enzyme-coupled 
spectrophotometric assay. One candidate, DNP-L-Arg, was the only one of the three with some 
experimental evidence of affecting kinase activity. The first assays suggested that DNP-L-Arg 
may have an activating effect on EphB4. The plausibility of this effect discussed with respect to 
mechanisms found in the literature, and using predicted and experimental structures for docked 
ligands. The coupled assay format did not conclusively confirm this effect. 
 The research presented underscores the ability for computational tools to be incorporated 
into a variety of different areas within the fields of biochemistry and drug design. Future 
complementary experimental work will be crucial both in evaluating and refining the suggested 
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This thesis is comprised of several projects with a unifying theme – the utilization of 
computational techniques and predictions to assist in experimental biochemical research and 
drug-design. Two of these projects focus on screening biologically relevant protein targets, 
carbonic anhydrase 9 (CAIX) and erythropoietin producing hepatocellular carcinoma receptor 
B4 (EphB4), for small molecule ligands that could have applications in diagnostics, therapeutics, 
or research. Another one of these projects describes the development of a computational protocol 
to create libraries of fluorescently-labelled ligand structures that would be useful for computer 
assisted drug design efforts, including those employed in the CAIX project. Each of these 
projects is described in detail in a separate chapter, with specific methods, materials, and results. 
Preceding these chapters is a general literature overview which provides relevant background 
information pertaining to all of the projects, and contextualizes this thesis with respect to current 
scientific literature. The theory underlying the methods used in these projects is given in the 
Methodology chapter, and is explained further in the appropriate subsequent chapters’ 
experimental sections. Finally, the results of these projects are summarized and directions for 







A review of relevant literature is reported as it pertains to the topics discussed in this 
dissertation. Certain techniques, both computational and experimental, are outlined briefly in 
context with the current methods and applications being used in the field. More complete 
methodological theory is given in “Chapter 3. Methodology”, while detailed procedural steps are 
described for each method in the chapters discussing their use (Chapters 4-6). 
2.2. COMPUTATIONAL TOOLS IN BIOINFORMATICS, DRUG-DESIGN, AND 
MEDICINAL CHEMISTRY 
2.2.1. Overview 
Computational tools have become increasingly used in fields like chemistry, biology, and 
medicine, often complementing traditional experimental techniques. The use of computers in 
these areas has facilitated the ability to process massive amounts of data that would otherwise be 
completely overwhelming. Bioinformatics is an emerging approach that focuses on processing 
and analyzing the wealth of information derived from biological systems, by interpreting it in the 
context of current molecular biology concepts through the application of computational and 
statistical techniques. Luscombe and co-authors define bioinformatics as “conceptualising 
biology in terms of molecules and applying ‘informatics techniques’ (derived from disciplines 
such as applied maths, computer science and statistics) to understand and organise the 
information associated with these molecules, on a large scale”.
1
 Some of the commonly applied 
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methods of modern bioinformatics will be described briefly in the following sections, with 
particular emphasis on techniques used in computer-assisted drug design. 
2.2.2. Sequence analyses and high-throughput data handling 
As of August 2013, the U.S. National Center for Biotechnology Information (NCBI) 
“GenBank” database contains over 167 million sequence records containing more than 154 
billion DNA bases, with the number of bases doubling roughly every 18 months since 1982.
2
 
Automated Sanger and next generation sequencing (NGS) technologies have made it 
increasingly possible to obtain large amounts of genomic data fast and cost effectively.
3
 This 
type of data can be used in a variety of applications including studies linking specific genetic 
variations or epigenetic markers to disease processes in genome-wide association studies 
(“GWAS”).
3
 However, as NGS technologies generate exponentially larger sets of data for a 
given assembled sequence than traditional methods, it has been suggested that data processing is 
likely to become the limiting factor for both the cost and time efficiency of NGS efforts.
3
 
Information obtained from sequences can be used to identify specific protein targets, or 
even variants of a protein target, for use in drug design efforts or diagnostic tests. Many 
sequence-based techniques are available that can use a given sequence, along with other 
information, to provide predictions about the structure and function of a given nucleotide or 
amino-acid sequence. For example, chromatin structure, gene regulatory information, and 
epigenetic markers can be studied in this way.
3
 Protein amino-acid sequences, either obtained 
directly or through gene sequencing, can similarly be analyzed for patterns suggestive of specific 
three dimensional structures, post-transcriptional modification sites, and other functional motifs. 
Multiple available resources are designed to assist in sequence analysis. Sequence alignment 
tools are important for comparing different sequences and determining the degree of similarity, 
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and for identifying common features or relationships. Many algorithms are available to perform 
these tasks, and they are often specialized for certain applications or types of sequences. 
Sequence alignment methods are normally categorized as either pairwise or multiple sequence 
alignment algorithms. Pairwise alignment tools are normally appropriate for aligning only two 
sequences, while multiple sequence alignments are suitable for aligning and comparing more 
than two sequences. Efficient use of computational time is an important consideration during the 
development of these software applications due to the very large size of these data sets.
4
 
2.2.3. General drug design approaches 
Computational tools are used to assist various stages of drug design. The physical 
properties of a drug or drug candidate can be estimated based on physical or empirical methods, 
and these can then be correlated with the molecule’s observed biological effects. For example, 
rational drug design may utilize information about specific target protein amino acid sequences, 
which can be analyzed, compared, or visualized using different software to generate optimised 
ligands for particular sites in the protein structure. While applications of computational 
techniques in drug design are diverse, they tend to be sub-categorized based on whether they rely 
solely on information about ligands, or on information about both ligand(s) and the therapeutic 
target. These categories are often referred to as “ligand-based” and “structure-based” drug design 
methods, respectively. 
2.2.3. a) Ligand-based drug design 
Ligand-based drug design techniques analyze the relationships between structural 
features of a series of ligands, and their observed biological effects. For example, a series of 
structurally related molecular derivatives may be tested in an animal or cell-line model at 
different doses, and a particular effect measured. The graphical relationship between the dose 
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given and the degree of effect observed is referred to as the “dose-response curve”. 
Computational techniques are often employed to describe quantitatively how the observed 
effects correlate with changes in ligand structure. This is known as a “quantitative structure-
activity relationship” or QSAR. QSAR studies use various molecular descriptors, such as charge, 
molecular weight, and surface area of a ligand, either empirically determined or computationally 
derived. Current methods rely on a combination of 2D and 3D molecular descriptors in their 
calculations. Once a QSAR is determined, it can be applied to untested molecules to predict 
which ones are likely to have the desired activity. QSAR studies have been used as a part of 
successful drug design strategy for numerous clinical candidates. For example, QSAR 
methodology has been integral to the development of selective HIV protease inhibitors.
5-8
 While 
QSAR studies can provide valuable information leading to the identification of active molecules, 
they may be seriously limited in their effectiveness and versatility. QSAR studies are often 
limited by the number and the diversity of molecules that were experimentally tested to generate 
the initial training set. Another potential deficiency of QSAR is rooted in some commonly used 
analytical methodologies that cannot guarantee that all tested molecules are eliciting their effects 
via the same target protein. Therefore, this approach is best suited to improving the activity of 




2.2.3. b) Structure-based drug design 
Structure-based drug design methods require structural information about both the ligand 
and the target. These methods commonly make use of protein structures experimentally 
determined through X-ray crystallography or NMR, or computationally modelled using the 





 Modern molecular biology methods have made it possible to reliably 
produce and purify samples of proteins or protein-ligand complexes to obtain X-ray 
crystallography-based models of their structures.
16
 Structure-based methods can be used to 
analyze interactions that occur within a protein-ligand complex, and provide valuable insights 
into mechanisms by which ligands affect protein activity. A representation of the chemical 
features needed to elicit or inhibit biological activity can be created in the form of a 
pharmacophore model. This approach generates a model that represents molecular features and 
their relative orientations that are responsible for imparting a desired biological activity.
17
 This 
method may use 3D information about a given set of ligands with known activities, about a given 
active site and its properties, or about a ligand-protein complex.
17
 A pharmacophore model can 
be used to screen libraries of compounds for ones that possess a required arrangement of 
features, or to design chemical compounds de novo, based on possible arrangements of 
substructures producing optimal interactions with the target.
17
 
Structure-based drug design efforts also make use of functions that can approximate the 
energy associated with interactions between the molecules of a system. Normally, molecular 
systems are described using either a classical mechanics or a quantum mechanics (QM) 
approach. Their reliance on first principles (without empirical assumptions) makes QM 
approaches highly appealing. These methods are considered to represent the most accurate 
analysis currently available. In addition to being used to describe structures and their associated 
potential energies, these methods can also be used to study dynamic intermolecular processes, 
such as reaction mechanisms. However, the use of quantum mechanical approaches, particularly 
for studying large biomolecules, remains heavily limited by the large amount of computational 
resources they require. QM methods are sometimes used to complement approaches where 
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classical potential energy functions are not adequate, such as in the case of describing catalytic 
mechanisms. Typically, however, protein-ligand systems are described through various classical 
approaches. Potential energy functions, in addition to being used to describe systems for the 
purposes of drug design, can also be used in combination with other techniques, such as 
molecular docking, to screen large libraries of chemical compounds to identify those that are 
likely to interact with a given target.
14-15, 18
 
2.2.4. Molecular docking and scoring for virtual ligand screening 
2.2.4. a) Docking algorithms for protein/ligand complexes 
Molecular docking involves the virtual placement of a small molecule (ligand) within a 
target protein binding site. This task is only seemingly simple, as both ligand and protein have 
varying conformational degrees of freedom, and varying conditions might affect conformations 
preferentially found in a natural system. These complications cannot be overlooked, as the 
appropriate sampling of each molecule’s conformational space is crucial in ensuring that any 
subsequent scoring analysis is biologically relevant. While there are many available algorithms 
to handle conformational searches, each can be classified under one of three general approaches: 
systematic, stochastic, and simulation-based methods.
18
 
Systematic approaches can provide very complete coverage of all reasonable 
conformations available to a particular ligand structure.
18
 Typically, these methods use strategies 
that either dock partial molecular fragments into a protein binding site and incrementally link 
them covalently to generate final conformers, or that dock rigid substructures and incrementally 
add flexible regions.
18
 Systematic searches can quickly become impractical even when 





 A systematic search that uses wide search increments may provide a subset 
of conformations that is very poorly representative of those actually available to the structure.  
Stochastic or random search algorithms are also used in different types of docking 
software. Two popular stochastic techniques are Monte Carlo and genetic search algorithms.
18
 
Using the Monte Carlo method, a random starting ligand conformer is scored and new 
conformations are randomly generated, scored and compared with the starting structure.
18
 
Conformers are selected if they have an improved energy relative to other conformers, or 
alternatively, if they passed a probability function test.
18
 
Simulation-based methods include those relying on molecular dynamics, where the time-
dependent behaviour of a molecular system is modelled to theoretically observe all possible 
conformational states.
18
 To reach all energy minima, high-energy barriers may need to be 
overcome, which can require excessively long simulation times. However, molecular dynamics 
simulation is a useful way of probing conformational space of a molecular system, if sufficient 
computational resources are available. 
2.2.4. b) Force field-based scoring methods for biological systems 
Force field-based scoring functions are commonly employed for estimating the potential 
energy of protein-ligand interactions. These potential energy functions are based on classical 
mechanics, and represent a compromise between overall accuracy and efficiency. Force fields 
can provide reliable estimates of structural conformation energies using limited resources. A 
force field potential energy function describes intra- and intermolecular forces as a summation of 
bonded (depending on bonds between atoms) and non-bonded terms. Non-bonded and bonded 
interactions are each described by a number of functions to account for multiple contributions to 
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the potential energy of a system. A given set of parameters is required, which provides different 
constants describing specific atom types and their characteristics. Parameter values can be 
determined empirically or calculated using quantum mechanics. It is not uncommon for a force 
field to use a set of parameters whose origin may be both empirical and theoretical. Dreiding is 
the all-atoms force field that is applied extensively throughout this manuscript, and it will be 
described in more detail in Chapter 3 – Methodology.
19
 
2.2.4. c) Virtual ligand screening and HierVLS 
Virtual ligand screening consists of screening large libraries of chemical compounds 
using computational methods to identify candidates with probable biological activity or other 
desired properties. Various methods, including some of those previously described, can be used 
to screen databases in this way. QSAR and pharmacophore modelling studies can use 
information obtained from test sets or experimental data to screen libraries according to the 
structure-activity relationships or models identified. Molecular docking and scoring can also be 
used to dock small molecules into a target protein cavity in a structure-based approach. “Hit” 
compounds from screening are often carried through to extensive experimental validation and 
optimization to produce a viable drug candidate.
18
 
Hierarchical virtual ligand screening (HierVLS) is a high-throughput protocol that docks 
different conformations of potential ligands into binding sites in a protein structure, and then 
scores them using a force field.
20
 HierVLS systematically passes the best scoring conformers 
through different filters to limit the most computationally expensive calculations to most 
promising conformers.
20
 A graphical user interface (GUI) for HierVLS has been developed to 
enhance user accessibility.
21
 HierVLS can be used in association with PASS to screen multiple 
binding sites within a protein's structure.
22
 PASS is a rapid and efficient program that uses a 
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geometry-based algorithm to identify putative binding pockets, basing their shape, size and depth 
relative to the protein surface.
22
 PASS is freely available and generates output that is generally 
compatible with applications used in later steps.  
HierVLS itself is a hierarchical approach to virtual ligand screening that tests the largest 
number of bound conformations of each ligand using the least computationally expensive 
methods, and proceeds to use more computational resources to obtain more accurate predictions 
of binding energy for the most promising conformers.
20
 A more detailed account of the HierVLS 
procedure is given in Chapter 3. HierVLS has been validated and used with several data sets and 
targets.
20, 23-26
 Most recently, HierVLS has been used as a part of a computational approach that 
successfully identified paclitaxel as an inhibitor of botulism neurotoxin A.
23
 
2.3. MOLECULAR IMAGING AND PROBE DEVELOPMENT 
2.3.1. Overview 
Molecular imaging is a modern medical imaging technique that can be applied both pre-
clinically and clinically during the development and application of therapeutic drugs. Molecular 
imaging differs from traditional anatomical imaging techniques in that it is capable of imaging 
functional processes involving target molecules. Molecular imaging can also provide structural 
information, either inherently or when combined with anatomical imaging techniques. Pre-
clinical molecular imaging is commonly used to assist in drug development, as it enables 
researchers to asses various drug characteristics in vivo using animal models prior to human 
clinical trials. Clinical molecular imaging is used in diagnostics, image-guided therapeutics, 






2.3.2. Molecular imaging in drug design 
There are several advantages to using molecular imaging as a tool in pre-clinical phases 
of drug design and development. Molecular imaging can provide real-time information about 
biochemical processes as they are occurring in vivo. In early investigations, molecular imaging 
can be used as a tool to aid in understanding the functional relationships between different 
potential therapeutic targets.
27
 Once a target is identified and a drug candidate produced, 
molecular imaging can also be used to experimentally evaluate drug performance in vivo, using 
animal models. Molecular imaging can be used to determine whether a drug candidate possesses 
the appropriate pharmacokinetic profile. This is possible because many molecular imaging 
techniques have a potential to be used quantitatively, and are inherently non or minimally 
invasive, so that functional processes can be imaged without disturbing the underlying 
physiology, and important information can be gleaned throughout the course of an experiment, 
instead of solely at the endpoint.
27
 
2.3.3. Clinical scope of molecular imaging 
Several molecular imaging techniques, including functional magnetic resonance imaging 
(fMRI) and positron emission tomography (PET) are routinely used clinically.
27-28
 These 
techniques are typically used for diagnostic purposes, and are designed to identify key molecular 
patterns or processes that are indicative of disease. Different molecular imaging techniques can 
be used either to image endogenous molecules or biomarkers, or to image processes involving 
exogenously administered reagents. Sometimes, contrast is achieved through fine tuning the 
inherent parameters of the imaging modality used to gain functional information, while in other 
instances, through the administration of an exogenous imaging agent or “probe”. The ability of 
different imaging modalities to image labelled reagents, which can be altered or targeted 
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specifically for the application, has sparked a great deal of interest in the development of target-
specific probes for various disease biomarkers. Probe development works similarly to the drug 
development process so that selective molecules are designed to target specific proteins. 
However, the desired characteristics of probe candidates will be different from those of 
therapeutic drugs, as they should be able to generate contrast for a desired imaging modality, and 
thus, would require different chemical and pharmacokinetic properties. For instance, while 
therapeutic drugs are often desired to be orally administrable, this is less important for imaging 
applications. Molecular imaging fits well into the idealized concept of “individualized 
medicine”, where the biochemistry of an individual’s pathology is characterized through imaging 
or other techniques and therapy is directed in a manner that is determined by that 
characterization. Subsequently, because of its potential for molecular targeting and it’s non-
invasiveness, molecular imaging can be used to predict response to targeted therapies and assess 
the response to therapy throughout the course of a selected treatment.
27-28
 
2.3.4. Molecular imaging modalities 
2.3.4. a) Functional MRI 
Magnetic resonance imaging, or MRI, is a very powerful and adaptable technique that 
can be used for numerous types of anatomical and functional imaging studies. MRI relies on the 
same underlying principle as another powerful analytical technique, nuclear magnetic resonance 
spectroscopy (NMR). MRI uses specially designed gradient magnetic fields to spatially encode a 
given sample, allowing an image to be reproduced from a given signal. MRI can use a variety of 
techniques for applying radiofrequency pulses and magnetic fields in order to generate special 
types of contrast based on different molecular environments. Typical anatomical MRI detects 
1
H 
nuclei that are found in water, which is highly abundant in the body. However, MRI can detect 
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various other nuclei with spin, as long as they are sufficiently abundant, meaning that it can also 
be used to provide information about chemical composition (spectroscopy). The versatility of 
MRI has been explored in many functional applications, relying on different techniques to 
generate contrast that enable the imaging of blood perfusion and oxygenation, as well as those 
that rely on exogenously administered contrast agents that can provide functional information. 
MRI is a highly sought-after technique because it does not require radioactive materials, and as 
such, is very safe for frequent or repeat imaging of patients.
29
 
2.3.4. b) Positron emission tomography 
Positron emission tomography (PET) is a technique used in nuclear medicine that is 
strictly a molecular or functional technique. It requires a tracer or probe, radiolabelled with a 
positron emitting isotope such as 
18
F, in order to generate contrast. Positron emitting isotopes can 
be generated in specialized facilities, such as cyclotrons, and must be prepared shortly in advance 
of administration and imaging due to their short half-lives (e.g., 
18
F half-life is 110 minutes).
28
 
While this process does require specialized facilities, it is advantageous because the precursors 
used (such as H2
18
O) are more safely and readily available compared to materials used to 
generate isotopes for other nuclear medicine technologies. In PET, a minute amount of probe 
labelled with a positron emitter is administered into the body. When a positron is emitted from 
the probe upon isotope decay, it inevitably encounters an electron. Upon colliding with the 
electron, two coincident gamma rays are produced at directions 180 apart. These gamma rays can 
then be detected by a gamma camera to produce an image. There are many ways in which a PET 
probe or tracer can be used to get functional information about a patient. PET is typically used in 





FDG). Actively growing tumours often exhibit enhanced glucose uptake and glycolysis 
 
14 
relative to surrounding tissue. FDG is used to probe relative glucose uptake of bodily tissues, 
exploiting this phenomenon to pinpoint tumour location and activity.
28
 FDG's utility comes in 
part from the fact that it can be phosphorylated, like glucose, in preparation for glycolysis upon 
entering the cell.
28
 However, because it lacks a key hydroxyl group at the 2- position occupied by 
18
F, it cannot be carried further through the normal glycolytic process.
28
 Thus, once 
phosphorylated, 
18





FDG is the most common application of PET in clinical use, there are many 
other types of PET tracers that either are being used or have a potential for development as 











These isotopes can be incorporated into various types of tracers for different applications.
28
 For 
example, water labelled with
15
O is to examine blood perfusion in tumours.
28
 PET has the 
advantage of being extremely sensitive (i.e., able to detect pM levels of injected probe) and 
depth-independent, meaning that developed tracers can be used in low enough concentrations so 
as to avoid possible toxic effects.
28
 The limited half-life of positron emitting isotopes is usually 
in the range of hours and intrinsically limits the overall radiation exposure of the patient. 
Development of novel PET probes and their utility requires compounds that are creatively 
designed to provide physiologically relevant information and that exhibit ideal pharmacokinetic 
profiles. It is also important to consider that, because of their short half-life positron emitting 
isotopes must be easily incorporated into tracers before use. Therefore, only rapid and high 
yielding reactions can be used to synthesize PET tracers. Modern imaging techniques often use 
PET in combination with anatomical imaging modalities such as CT to provide more complete 





2.3.4. c) Fluorescence imaging 
Fluorescence imaging is an optical technique that has recently gained utility in the 
clinical setting, but that has long been useful for pre-clinical work and experimental 
biochemistry. There are various properties that can be exploited in optical and specifically 
fluorescence-based imaging in order to probe various characteristics of biological systems. 
Fluorescence occurs when certain molecules, known as fluorophores, are excited with a photon 
of a particular wavelength. Some of the absorbed energy is reemitted at a higher wavelength of 
light (lower energy) in the process known as fluorescence.
30
 Simple excitation and emission are 
useful in the context of imaging or detection, but other optical properties can be also used to 
obtain valuable information. These properties include fluorescence anisotropy, polarization, and 
fluorescence-resonance energy transfer.
31-32
 Fluorescent molecules are commonly imaged using 
fluorescence microscopy. Specific probes, often antibodies, are labelled with a fluorescent dye 
and when bound to proteins or other molecules of interest provide useful molecular-level 
contrast.
33
 Fluorescence-based imaging techniques have improved to a point that they may be 
used to obtain images through shallow tissue depths of up to a few centimeters.
34
 Range and 
interference from autofluorescence are improved by utilizing fluorescent moieties that emit light 
in the near-infrared (NIR) range of the electromagnetic spectrum.
34
 NIR wavelengths are poorly 
absorbed by water and hemoglobin, so use of NIR-emitting probes improves signal penetration 
and reduce changes in signal due to physiological composition.
34
 While in vitro techniques 
typically use labelled antibodies, and fluorophores with varying optical properties, in vivo 
applications require differently specialized reagents. Antibodies generally have poor 
bioavailability and biodistribution, and have serious problems with immunogenicity and cost-
effectiveness. Fluorophore-labelled small molecules that are specific for molecular targets would 
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be significantly more suitable for this type of application. Specialized fluorophores and vehicles 
for fluorophore delivery represent an area of ongoing research.
35-38
 
Several types of probes can be developed for use in in vivo and cellular imaging. For 
example, probes can be intrinsically fluorescent and directly target a particular protein. These 
probes can be designed to either bind reversibly with very high affinity, or through covalent 
bonds linking the probe to the target protein. The probe can also be “activatable”, where a 
fluorescent moiety is covalently linked to a quencher, which limits fluorescence activity until it 
is covalently modified, such as through the action of an enzyme. Activatable probes could be 
used to quantify enzymatic activity if they can act as substrates for a particular enzyme that 
would remove the quencher and enable a fluorescent signal. This type of action would be 
advantageous because it amplifies the amount of signal produced, as multiple probes could be 
activated by a single enzyme molecule. This type of activated probe could be designed with 
properties that would trap the fluorescent moiety, once cleaved from the quencher, inside of the 
cell or an organelle of interest, so that the signal remains “trapped” and more efficiently localized 
to the area of interest.
35, 39
 
2.4. BIOMARKERS FOR CERVICAL CANCER AND ASSOCIATED HYPOXIA 
2.4.1. Cervical cancer etiology and human papillomavirus 
Cervical cancer is the second most common type of cancer affecting women worldwide, 
with an estimated 529,409 new cases developing in 2008.
40
 Human papillomavirus (HPV) 
infection has been firmly established as the cause of nearly 100% of cervical cancer cases.
40
 
HPV infection also contributes to the development of a significant number of observed cases of 
anogenital and head & neck carcinomas.
40
 While over 100 HPV subtypes have been identified, a 
specific subset of these are considered oncogenic or likely oncogenic. HPV-16 and HPV-18 are 
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two of the most common oncogenic subtypes and account for over 70% of cervical neoplasias.
40-
42
 While the role of HPV in the etiology of cervical cancer is quite clear, it is also understood that 
there are other factors influencing the progression from oncogenic HPV infection to persistence 
and cervical neoplasia. Though at least half of sexually active women will develop an HPV 
infection during their life, most infections are cleared within a period of several months from the 
time of infection, with no apparent lasting pathology. However, in some cases, infection with an 
oncogenic HPV subtype becomes persistent and leads to the development of either a progressive 
low-grade intraepithelial lesion, or a high-grade intraepithelial lesion, either of which may 
develop into invasive cervical cancer over a period of one to several decades
40-41, 43




In developed nations, the implementation of screening programs such as cytological Pap 
tests has enabled early detection and treatment of precancerous and cancerous lesions, lowering 
the incidence of invasive cervical cancer as well as its mortality rate.
42, 44-46
 The recent 
development, approval, and implementation of prophylactic vaccination programs for certain 
HPV subtypes is also expected to further decrease the burden of this disease.
47
 Despite current 
successes in early diagnosis and treatment of cervical cancer, there remains a clinical application 
for rapid, specific, and selective diagnostic and prognostic tools. Current cytology-based 
methods are quite selective and specific in the detection of abnormal lesions, though there is still 
potential for improvement on this front. Cytology-based methods are intrinsically subjective, 
require complex laboratory infrastructure, and do not necessarily provide a large amount of 
information about the risk status of the HPV infection and the lesion, which would be useful in 
order to better direct therapy.
42, 44-46
 With the discovery of the role of HPV in cervical cancer, 
and subsequent research, many clinical diagnostic tests have been developed that are designed to 
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test specifically for HPV.
42, 44-45
 Despite the high specificity of some of these tests, many of them 
are poorly selective for high-risk HPV infections showing signs of precancerous lesion. This is 
likely due to cross-reactivity with other subtypes of HPV.
42
 The presence of an oncogenic 
subtype of HPV does not necessarily predict that an individual is developing or has developed a 
cancerous lesion. Current clinical recommendations do not include HPV-specific testing as part 
of the screening regimen for young women (ages 18-29) due to these concerns.
42
 However, 




Current re-examination of the screening methodologies used for HPV-related cervical 
cancer highlights the need for specific markers able to detect clinically relevant cases of 
oncogenic HPV, providing prognostic information that can better direct therapy. Pre-clinical and 
clinical cervical cancer monitoring would also benefit from detection tools that are minimally 
invasive that can provide a measurable indication of the response of a tumour to a specific 
therapy or treatment. 
2.4.2. Tumour-related hypoxia 
Tissue hypoxia arises when a particular part of the body is deprived of an adequate 
supply of oxygen. Tumour-associated hypoxia is often characteristic of locally advanced solid 
tumours and is known to play an important role in tumour pathogenesis.
48
 While it is a complex 
process, tumour hypoxia is generally arises as the result of an imbalance in the supply (through 
blood perfusion and diffusion) and demand of oxygen.
48-49
 A hypoxic tumour microenvironment 
can lead to gene-regulatory changes that alter the cell phenotype.
48
 In patients with advanced 
cervical cancer, low tumour oxygenation has been repeatedly associated with an aggressive 





 Hypoxia can induce paradoxical cellular effects.
48-49
 While low oxygenation can 
induce apoptosis and retard cell growth, it can also enhance growth, the formation of metastases, 
and invasiveness in some cancer cells.
48-49, 54-55
 Hypoxia-inducible factor (HIF) is a family of 
transcription factors that is responsible for changing gene expression upon exposure to hypoxic 
conditions.
49
 HIF-1α is a transcription factor that controls expression of several enzymes, and 




2.4.3. Carbonic anhydrase IX as a biomarker for cervical cancer 
2.4.3. a) Carbonic anhydrase structure and function 
Carbonic anhydrases (CAs) are enzymes that catalyze the reversible hydration of carbon 




Figure 2.4.3-1–Carbonic anhydrases catalyze the reversible hydration of carbon dioxide. Figure 
generated using ChemDraw Software (Perkin Elmer). 
CAs are crucial to many physiological processes including the maintenance of intra and 
extracellular pH, as well as gas exchange with red blood cells.
56-59
 CAs are encoded by 5 
unrelated gene families α, β, γ, δ, ζ that have little or no sequence similarity.
63
 Mammalian CAs 
belong to the α-class, and exist in many isoforms. αCAs invariably contain Zn
2+
, which is 
essential for catalytic activity.
59-62
 There are 16 mammalian αCA and CA-like isoforms, 13 of 
which are active.
62-63
 Active mammalian CA isoforms are differentially localized within the cell, 
with I-III, and VII, XIII isoforms being found predominantly in the cytosol, VA and VB in 
mitochondria, IV, IX, XII, XIV, and XV associated with the plasma membrane, and VI secreted 
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into the extracellular space.
62-63
 A complete representation of the localizations of mammalian CA 
isoforms is shown in Figure 2.4.3-2. 
 
Figure 2.4.3-2-A basic cell representation depicting the relative localization of 13 different 
mammalian carbonic anhydrase (CA) isoforms. Isoforms IV, IX, XII, XIV, and XV are 
membrane-associated, VI is secreted, VA and VB are located in the mitochondria, and I-III, and 
VII, XIII are cytosolic.
63
 Figure generated using ChemDraw Software (Perkin Elmer). 
2.4.3. b) Carbonic anhydrase catalytic mechanism 
The catalytic activity and mechanism of CAs has been well characterized, particularly 
with respect to the α family.
59-62, 64
 αCAs rely on a Zn
2+
 in the active site which is co-ordinated 
by three histidine residues.
59-64
 Isoforms that do not contain these key residues, such as VIII, X, 
and XI, are inactive.
63
 The following description of carbonic anhydrase mechanism has been 
summarized from several more detailed reviews
59-62, 64
, and refers to Figure 3 of a manuscript 
published in Bioorganic & Medicinal Chemistry by Supuran et al (2007) which is reproduced, 




Figure 2.4.3-3–“Schematic representation of the catalytic mechanism for the α-CA catalyzed 




The zinc is located at the bottom of a deep cleft, and in addition to the three histidines, is 
coordinated by either a hydroxide (A) or water molecule (D) in the active and inactive form, 
respectively. The CO2 substrate is held by a hydrophobic pocket of the active site (B). Hydrogen 
bonding interactions between the coordinated hydroxide and surrounding residues increase the 
nucleophilicity of the water and assist in positioning the CO2 substrate. The nucleophilic 
hydroxide attacks the CO2 substrate, forming bicarbonate, which remains coordinated to 
Zn
2+
(C). A water molecule displaces the bicarbonate, which is released (D). The resultant form 
of the enzyme, which contains zinc coordinated to water (D), is inactive. The active, basic form 
is regenerated through a proton transfer reaction which is assisted by adjacent residues, such as 
histidine (in the case of isoforms II and IX, among others) which acts as a proton “shuttle”. This 






2.4.3. c) Evidence for carbonic anhydrase IX as a biomarker 
Carbonic anhydrase IX (CAIX) is a CA isoform that is expressed in several tumour types, 
including cervical cancer, and is rarely expressed in healthy tissues outside of the gastrointestinal 
tract.
49, 58
 CAIX is tethered to the plasma membrane by a transmembrane domain, with the 
catalytic domain located in the extracellular space.
63
 CAIX activity and expression are associated 
with tumour-related hypoxia. CAIX transcription is induced when hypoxia-inducible 
transcription factor (HIF)-1α binds to the promoter of the CAIX gene.
49
 HIF-1 and other 
transcription factors also regulate other genes responsible for phenotype changes associated with 
hypoxia.
49
 For example, in low oxygen conditions, cell metabolism shifts from oxidative 
phosphorylation to high levels of glycolysis, which requires increased expression of glycolytic 
enzymes and glucose transporters.
49
 
CAIX expression is thought to occur as a part of this adaptive response in advanced 
carcinomas for maintaining neutral intracellular pH while there is a high rate of aerobic 
glycolysis, with the by-product being extracellular acidification.
49, 56, 58, 65
 Acidification of the 
extracellular tumor microenvironment appears to contribute to an aggressive tumour 
phenotype.
49
 There is increasing evidence that CAIX expression in tumours correlates 
significantly with an increased invasiveness, increased likelihood of metastasis, and a poor 
overall survival.
50, 54, 66
 A study by Loncaster et al (2001) demonstrated that in addition to being 
expressed in 79% of human cervical tumours sampled, CAIX is a significant prognostic indicator 
for disease-free and metastasis-free survival in a manner that is independent of disease stage.
50
 
The authors suggest that CAIX, in combination with information about disease stage could be 
predictive of factors like response to therapy and disease outcome. Using a much larger sample, 
Woelber et al (2011) further corroborated these findings, demonstrating that nearly 82% of 
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specimens tested expressed significant levels of CAIX, and that samples expressing moderate to 
high levels of CAIX were significantly correlated with advanced tumour stage, greater invasion 
depth, and undifferentiated tumour grade.
66
 There was also a noted correlation between the 
number of metastatic lymph nodes present and expression of CAIX. These and other 
investigations have led CAIX to become the target of imaging probe and anticancer drug 
development.
61
 Many investigations have identified selective and potent inhibitors of CAIX.
36, 61, 
67-68
 A 2011 investigation demonstrated that decreased CAIX expression and CAIX inhibition 
separately resulted in decreased metastasis and decreased tumour growth using cell culture and 
animal models.
68
. Fluorescent inhibitors and other imaging agents have also been identified and 
experimentally tested using cell culture and animal models.
36, 69-74
 In 2005, Cecchi et al reported 
a series of fluorescent sulfonamides that act as dual imaging probes and therapeutic inhibitors of 
CAIX, and demonstrated that these compounds specifically targeted hypoxic cells expressing 
CAIX.
36
 CAIX is clearly a high priority target for anti-cancer therapeutics. However, its 
expression and activity have also been shown to provide information about tumour pathology 
that is highly relevant to diagnostic and prognostic applications.
49, 61
 The development of probes 
for prognostic and diagnostic imaging and response to therapy, particularly for use in pre-clinical 
research, are important and ongoing areas of research.
49, 61
 
2.5. RECEPTOR TYROSINE KINASES AS DRUG TARGETS 
2.5.1. Structure and function of receptor tyrosine kinases 
Receptor tyrosine kinases (RTKs) are transmembrane proteins that respond to 
extracellular ligands by catalyzing intracellular autophosphorylation and transphosphorylation on 






2.5.2. Eph receptors 
The Eph family of receptor tyrosine kinases consists of sixteen members, fourteen of 
which have been identified in humans. Eph receptors belong to a subgroup, A (EphA receptors, 
EphA1-EphA10) or B (EphB receptors, EphB1-EphB6), based on their tendency to interact with 
ephrin-A or ephrin-B ligands, respectively.
76
 Six type-A ephrins (ephrin-A - ephrin-A6) are 
tethered to the cell surface via a glycosylphosphatidylinositol (GPI) linker, while type-B ephrins 
(ephrin-B1 – ephrin-B3) possess a transmembrane domain linked to an intracellular domain, 
which can initiate downstream signaling events in a phenomenon known as “reverse 
signaling”(Figure 2.5.3-1).
77-80
 The term “reverse signaling” is used to refer specifically to the 
signal that is propagated in the direction of the ephrin ligand, differentiating it from the activity 
of the Eph receptor itself. 
All Eph receptors share a conserved sequence of structural domains. The extracellular 
portion of these receptors consists of a globular ephrin-binding domain, a cysteine-rich region 
and two fibronectin type-III repeats. The intracellular portion is linked to the extracellular 
domain by one transmembrane domain, and consists of a juxtamembrane region followed 
sequentially by the catalytic (tyrosine kinase) domain, as well as SAM and PDZ domains.
77-88
 
Kinase domains of Eph receptors share a high degree of structure and sequence homology with 
catalytic domains of other tyrosine kinases, including insulin receptor kinase (IRK) and 
epidermal growth factor receptor (EGFR).
89-90
 
The juxtamembrane segment (JMS) is a short (approximate 10 amino-acid) sequence that 
is located N-terminally on the kinase domain of Eph receptors. The kinase domain contains one 
N-terminal and one C-terminal lobe. The N-terminal lobe generally consists of a 5-stranded β 
sheet that adopts a twisted structure (strands denoted by β1 to β5), along with one α-helix (αC). 
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αA and αB are short helical regions that are found in the JMS, and the nomenclature here reflects 
that used to previously describe the EphB2 structure (PDB: 1JPA).
91
 The C-terminal lobe 
consists mainly of helices, and is slightly larger than the N-terminal lobe. The N- and C- terminal 
lobes are connected by a short “hinge” linker, which forms a flexible inter-lobe cleft. Structural 
biology studies involving insulin receptor kinase (IRK), EphB2, and EphA4 have described the 
mechanistic details of kinase activation and catalysis in substantial detail.
86, 91-93
 Several key 
regions within the β-sheet and connecting loops are responsible for coordinating ATP within the 
active site, while the C-terminal lobe is associated with coordinating the peptide substrate. A 
flexible activation (A) loop structure spans the cleft between the two lobes, and plays a key role 
in regulating kinase activity. Several conserved tyrosine residues in the JMS and A-loop are 
known to be sites for trans- and auto-phosphorylation. Phosphotyrosines, which are the products 
of the autuphosphorylation activity, can sometimes serve as key docking sites for downstream 
effector molecules possessing SH2 homology domains. The phosphorylation of specific tyrosine 
residues, including Tyr984, can also produce intramolecular conformational changes that are 
responsible for activating the kinase by promoting the catalytically competent conformation. In 
an autoinhibited kinase, the dephosphorylated A-loop acts as a pseudo-substrate inhibitor, 
blocking access of the peptide substrate to its binding site. Upon phosphorylation of A-loop 
tyrosines, however, the A-loop changes conformation and substrate access to the active site is 
restored. The EphB2 crystal structure (PDB:1JPA) demonstrates that in the autoinhibited state, 
the JMS associates closely with the N-terminal lobe, perturbing the position of catalytic residues 
and preventing the activation loop from assuming an “active” conformation.
91
 The JMS 
associates with both the N- and C- terminal lobes, likely restricting inter-lobe flexibility. 
Auto/trans phosphorylation was postulated to destabilize these interactions, promoting the active 
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conformation. NMR and X-ray crystal structure data obtained for EphB2 and EphA4 constructs 
support these hypotheses, and suggest that the kinase domain dynamically adopts a range of 
conformations in solution, and increased flexibility is associated with increased catalytic 
ability.
91
 Similar conformations have been observed for the insulin-like growth factor receptor 1, 
indicating a conserved functional mechanism. Li and co-authors postulate that the β-sheet/αC 
cleft could be targeted by small molecules which would displace (or equivalent residue as several 




There are several studies in the literature, which suggest that it is possible to use a small 
molecule to activate an isolated tyrosine kinase, possibly by affecting one of the mechanisms 
described above. In 2001, DMAQ-B1, a small molecule isolated from a tropical microbial 
extract, was found to specifically activate IRK in an insulin-independent manner.
94
 It was 
proposed that the autoinhibitory conformation of the IR kinase was altered upon DMAQ-B1 
binding. Protease sensitivity experiments suggested that DMAQ-B1 altered the conformation of 
IRK in regions proximal to the ATP-binding site. The same year, TLK16998, another small-
molecule IRK activator, was found to sensitize cells to insulin, acting specifically on the kinase 
domain.
95
 While these activities have been characterized in vitro and in vivo, the exact 
mechanism of activation remains unclear. 
These previous investigations highlighted the potential for the development of allosteric 
tyrosine kinase activators. Due to their critical and somewhat ubiquitous role in cell signaling 
and development, receptor tyrosine kinases have been extensively studied, largely in the context 
of therapeutic inhibition. Though the inhibition of some specific tyrosine kinase-mediated 
signaling pathways seems to be desirable in the context of anti-cancer drug development, the 
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complex action of Eph receptors and other tyrosine kinases in cell regulation begs for the 
identification of both positive and negative modulators for these enzymes. The use of such 
modulators in research can provide valuable insights on the role of Ephs in specific cellular 
processes by enabling researchers to specifically activate these enzymes in vitro and in vivo for 
the purpose of investigating their roles in cellular processes. Novel therapeutic approaches could 
also make use of specific Eph activators, as the activity of these receptors is crucial for the 
positive or negative regulation of various biological processes, including bone resorption, blood 
vessel growth, cell differentiation, and cancer invasiveness.
77-80, 82, 87-88, 96-97
 To date, there are no 
specific small-molecule allosteric activators of the Eph receptor family that have been reported. 
The high degree of structural and functional conservation between tyrosine kinases makes it 
reasonable to expect that mechanisms exploited for drug-development in Ephs would also be 
useful in the context of related proteins.
75, 86, 89, 91-92, 94, 98-99
  
2.5.3. EphB4 and ephrins-B2 signalling in cancer 
EphB4 is a receptor tyrosine kinase whose endogenous ligand is the transmembrane 
protein ephrin-B2.
82
 These two proteins interact in the extracellular space between adjacent cells, 
initiating a bidirectional signal in their host cells.
77
 The signalling that occurs as a result of Eph 
receptor activation is normally termed “forward signalling” while ephrin signalling is referred to 




Figure 2.5.3-1-EphB4 receptors and their endogenous ligand, ephrin-B2, can interact between 
two neighboring cells and trigger a bidirectional signal. Stimulated activity and signalling that 
occurs in the EphB4-containing cell is termed “forward signalling” while activity that is 
stimulated in ephrin-B2 direction is termed “reverse signalling”. Figure generated using 
ChemDraw Software (Perkin Elmer).  
EphB4 is able to dimerize and oligomerize with other EphB receptors, promoting the tyrosine 
kinase activity of these enzymes.
78
 The EphB4 receptor and its ephrin-B2 ligand are critically 
involved in the development of new blood vessels from existing cardiovascular structures in a 
process known as angiogenesis.
79-80, 82, 85, 87, 96, 100
 EphB4 expression is significantly upregulated 
in some types of cancer including breast, gastric, and colon carcinoma.
101-103
 Differentially high 
EphB4 expression has also been observed in cells lining vasculature.
82, 101
 Disrupting 
EphB4/Ephrin-B2 binding has been suggested as a viable chemotherapeutic approach that retards 
tumor growth by inhibiting vessel development, therefore depriving cancer cells of nutrients.
85, 
101, 104
 Monoclonal antibodies that target the EphB4 ephrin-binding domain and impair EphB4-
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ephrin-B2 signalling have been shown to inhibit angiogenesis and growth in human tumour 
xenografts in mice.
104
 Several small-molecule inhibitors of the EphB4 kinase domain have been 
reported
83, 105-112
, but there has yet to be a selective EphB4 kinase inhibitor approved for clinical 
treatment. Nevertheless, previous success in therapeutically targeting tyrosine kinases suggests 
that this approach is warranted in biologically relevant proteins of this family.
75
 Novel selective 
EphB4 kinase inhibitors are desirable lead compounds to be further optimized for use as 
chemotherapeutic drugs. In addition, the EphB4 ephrin-binding domain can also be selectively 
targeted with the aim of disrupting EphB4-ephrin signalling. Currently, only peptides mimicking 
the ephrin-B2 interaction sequence have been identified as ligands for this domain.
84, 113
 Previous 
success in RTK-based therapies suggests that this approach is warranted in biologically relevant 
proteins of this family.
75
 EphB4 specific molecules could also have potential roles in cancer 
diagnosis and treatment. EphB4 involvement in cancer development and prognosis makes it a 
potentially useful biomarker for functional imaging modalities like (PET).
114
 Probes labelled 
with positron-emitting isotopes could be used with PET to visualize tissues expressing high 
levels of EphB4, indicating the presence of cancerous cells. Information about the expression of 
EphB4 in a tumour could also provide prognostic information, based on the observation that high 




2.6. SUMMARY & SCOPE 
The fields of drug design and medicinal chemistry have expanding horizons with the 
advent of novel computational techniques that can aid in the discovery and development process, 
and have an increased scope, as molecular imaging techniques expand the applications of 
targeted small molecules. 
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My project aims to use a series of computational techniques, including high-throughput 
molecular docking and scoring, against two biologically relevant targets, EphB4 and CAIX, with 
the ultimate aim of developing novel therapeutic or diagnostic agents. For CAIX probe 
development, ligand binding site preference will be estimated in order to predict whether the 
probe is likely to be isoform specific, and whether it is likely to interfere with enzymatic activity. 
Certain applications, such as evaluating response to an existing therapy in an experimental 
setting, may require that the probe does not interfere with activity of the molecule of interest 
(CAIX). In the process of attempting to discover selective molecules for these targets, this 
project also aims to develop a protocol for incorporating imaging agents into the screening 
process. Fluorescence imaging, in particular, will be utilized with an approach for producing 
large computational libraries of fluorescently labelled compounds, so that these can be screened 
and examined with the computational techniques available.  
The overall scope of this project has been segmented into three distinct chapters. The first 
chapter outlines the development of a protocol for designing and computationally screening 
libraries of fluorescently labelled compounds. The second describes how a library of fluorescent 
compounds was used to identify potential optical probes for CAIX. The third describes the use of 
virtual ligand screening for identifying putative ligands for EphB4, and subsequent experimental 
validation of selected of candidates. 
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This chapter will review the methods used in the subsequent chapters, focusing on the theory 
underlying each method. Methods will be described more briefly in their corresponding 
manuscripts, and specific procedural details will be provided there. 
3.2. COMPUTATIONAL METHODS 
3.2.1. Force field-based methods 
Recall that force fields are potential energy functions that can be used to approximate the 
energy of protein-ligand interactions and to minimize the geometry of molecule structures. Force 
fields are particularly common and useful in applications, such as structural biology and 
computer-assisted drug design where the molecules of interest are very large. While quantum 
mechanics-based approaches are more accurate at describing molecular systems, they remain 
prohibitively expensive from a computational standpoint, for many applications, particularly 
those of a high-throughput nature. In these situations, force fields can be used to get informative 
results that require fewer resources. Force fields describe different forces within a molecular 
system using classical mechanics. The various intra and intermolecular forces are approximated 
individually in separate terms, and summed together to yield the final potential energy function. 
There are many available force fields, many of which have been designed and optimized for 
specific types of molecules or applications. Dreiding is the all-atoms force field used by the 
HierVLS scheme. Its versatility is useful for handling both protein, and ligand structures during 
the course of docking and scoring. A basic overview the Dreiding methodology is given in the 
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following paragraphs, summarized from the publication by Mayo et al, which completely 
describes the design and parameterization of this force field.
1
 While the functions used to 
describe different atomic interactions may vary between different force fields, the general 
scheme described for Dreiding is representative of what is used by other force fields.
2-3
 
In Dreiding, the potential function is given as the summation of the terms for bonded and 
non-bonded molecular interactions (Equation 3.2.1-1): 
Equation 3.2.1-1 - Force field potential energy functions are summations of both bonded and 
non-bonded terms. 
                               
Interactions between bonded atoms include bond stretching, bond angle bend, dihedral angle 
torsion, and inversion terms. Due to the tendency for starting structures to have very approximate 
geometries Dreiding by default describes bond stretching using simple harmonic oscillation 
(Equation 3.2.1-2):  
Equation 3.2.1-2 - Simple harmonic oscillation function for bond stretching term. R denotes 




        
  
Alternatively, Dreiding can use a more accurate Morse function for further refinement of the 
initial simple harmonic oscillator function, if specified. Bond angle bending is described using a 
harmonic (cosine form) function ( 
 
Equation 3.2.1-3) with equilibrium angles (θj
0




Equation 3.2.1-3 - Function describing the bond angle bending for two bonds between atoms IJ 
and JK (J atom shared). CIJK is a function of the force constant and the equilibrium angle:  





     
 
 
                  
    
When the equilibrium geometry is linear (180º), this is instead approximated by Equation 
3.2.1-4.  
Equation 3.2.1-4 - Bond angle bending for molecules with linear equilibrium geometry is given 
by this potential. 
                    
  
Dihedral angle torsion about four atoms (IJKL) is described as a function of the dihedral angle 
(φ), the equilibrium angle (φJK
0
), the periodicity (nJK), and the barrier to rotation (VJK) (Equation 
3.2.1-5). 
Equation 3.2.1-5 - Dihedral angle torsion is described about four atoms (IJKL) with respect to 
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 The inversion term (for atoms bonded to three other atoms) is given by Equation 3.2.1-6. 
Equation 3.2.1-6 - Cases where one atom, I, is bonded to three other atoms, JKL, may require 
the inclusion of an inversion term which is given as a function of CI, and the angle between the 






      
 
 
             
    
This function differs from those used by certain force fields intended for biological simulations, 
which treat inversion as improper torsion. Non-bonded terms included describe van der Waals 
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forces, electrostatic interactions, and hydrogen bonding. Van der Waals and electrostatic 
interactions are only calculated between atoms that are not already described by a bonded 
interaction. Van der waals forces are, by default, described using a 12-6 Leonard-Jones potential 
given by Equation 3.2.1-7. 
Equation 3.2.1-7 - A 12-6Leonard-Jones potential is used to calculate van der Waals forces as a 
function of interatomic distance (r). 
     
 





Electrostatic forces are calculated using the Coulombic expression shown in Equation 3.2.1-8.  
Equation 3.2.1-8 - Electrostatic forces are calculated using a Coulombic interaction expression. 
Qi,j refer to atomic charges, ϵ, the dielectric constant, and Rij the interatomic distance. 322.0637 
is used as a conversion factor for kcal. 
   
              
    
 
Hydrogen atoms that are bonded to very electronegative atoms and that might participate in 
hydrogen bond donation are specially typed. When these hydrogen atoms are in close proximity 
to a hydrogen bond acceptor, van der Waals and electrostatic forces are calculated for this set of 
atoms, and a specific hydrogen-bonding potential function (Equation 3.2.1-9) is applied. 
Equation 3.2.1-9– A potential used to describe hydrogen bonding in Dreiding as a function of 
the distance between the donor and acceptor atoms (RDA) and the bond angle between donor and 
acceptor atoms (θDA). Dhb and Rhb values can be derived from quantum mechanical calculations 
or empirically. 
                  
             
               
 Generally, Dreiding is a relatively simple force field but has been designed to be versatile 
enough to be used with various types of molecules. Many commercial and non-commercial 
software packages include different force fields that are designed for use with particular types of 
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systems. For example, the MOE software used in different subsequent chapters features a set of 




3.2.2. Hierarchical virtual ligand screening 
Hierarchical virtual ligand screening (HierVLS) is a structure-based method for high-
throughput docking and scoring of large ligand libraries against 3D protein target structures.
5
 
HierVLS identifies and filters promising binding conformations through a series of steps to 
ensure that the most computational time (and therefore, the best estimates of binding) are 
provided for the most promising conformers of a library.
5
 
HierVLS is executable through a graphical, interactive user interface (GUI).
6
 The 
HierVLS protocol begins with an input defining the available binding sites for the given protein 
structure. These binding sites can be user-specified (such as might be the case for an 
experimentally determined structure with a well-defined site of interest) or can be generated 
using an algorithm that scans the surface of the protein structure for cavities. In the following 
chapters, HierVLS is implemented with such an algorithm, PASS, to rapidly identify potential 
sites within the protein structure using a geometric algorithm that characterizes available binding 
cavities by their shape, size, and depth with respect to the surface of the target structure.
5, 7-8
 
The user supplies molecule structure files for both the protein target and ligand library to 
be screened. Atoms must be appropriately typed for handling by the force field and solvation 
model. Gasteiger atomic charges are set for all ligands to be docked.
9
 The initial set of docked 
ligand conformations are generated using the Dock4.0 software package.
10
 Dock4.0 calculates an 
energy grid to determine the energy contribution to docked conformers from the protein 
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including any water molecules that are part of the protein structure provided. The initial 
conformations are evaluated based on the percentage of buried surface area and the number of 
hydrogen bonding interactions predicted between the protein and ligand structures. Conformers 
that do not have a user-defined percentage of buried surface area are eliminated. The remaining 
best conformers (a specified number, N) are carried through to the next step, Level 1. During 
Level 1, each ligand structure is energy minimized while keeping the protein structure fixed 
using the Dreiding force field without accounting for solvation effects. The lowest energy 
conformers from level 1 (usually a small number depending on available computational 
resources) are re-evaluated using the analytical volume generalized borne solvation method 
(AVGB), which is applied both to the free ligand, and the protein-ligand complex.
11
 Final 
binding scores are obtained by calculating the difference in energy between the protein-ligand 
complex and the solvated protein and ligand alone as shown in Equation 3.2.2-1. 
Equation 3.2.2-1 – The binding affinities for the best conformers from Level 1 of HierVLS are 
calculated by subtracting both the energy of the solvated protein alone and the solvated ligand 
alone from the energy of the solvated complex. The AVGB solvation approach is used to 
calculate solvation energies. 
                            –                                                  ) 
3.3. EXPERIMENTAL METHODS 
3.3.1. Fluorescence-based binding assays 
3.3.1. a) Fluorescence polarization 
Fluorescence polarization is a phenomenon that occurs because fluorophores are excited 
maximally when their absorption transition vectors are aligned in parallel with respect to the 
excitation source.
12
 Linearly polarized light can be used to selectively excite optimally aligned 
molecules.
12
 The motion of the fluorophore prior to the emission (fluorescence) will affect the 
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degree to which this polarization is maintained. When a fluorescent molecule is free to rotate 
rapidly in solution and is excited by polarized light, the emitted light tends to be scattered in 
multiple planes, resulting in low polarization.
13
 However, if the fluorophore becomes bound into 
a larger, less mobile complex, there is less movement prior to light emission, and a high 
polarization value is obtained.
12-13
 This principle can be used to compare the fluorescence 
polarization of an unbound molecule with a bound complex to identify an intermolecular binding 
event.
12-13
 Fluorescence polarization can be calculated as a function of the fluorescence intensity 
parallel and perpendicular to the plane of excitation (Equation 3.3.1-1).
12
 
Equation 3.3.1-1– Fluorescence polarization is calculated as the ratio of the difference between 
the fluorescence intensity parallel and perpendicular to the excitation plane to the sum of these 
intensities. 
  
      
      
 
3.3.1. b) Fluorescence resonance energy transfer 
Fluorescence resonance energy transfer (FRET) is another mechanism through which 
intermolecular interactions can be probed using fluorophores. FRET requires donor and acceptor 
moieties that are in close proximity. When excited, a donor molecule can transfer this energy to 
the acceptor molecule, which then emits a detectable photon.
12
 FRET donors and acceptor pairs 
can consist of two different molecules, but the acceptor must be excited at emission wavelengths 
of the donor molecule.
12
 The relatively close proximity required for FRET to occur (10-100Å) 
makes this a useful tool to detect binding interactions between two molecules, each containing a 
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Creating databases of fluorescently-labelled compounds for the 




Many techniques in molecular biology laboratories demand the use of fluorescent 
reagents, which often function as optical tracers. These molecules may be intrinsically 
fluorescent or labelled with a fluorophore moiety. Chemically reactive fluorophores selective for 
biologically relevant functional groups are commonly used for labeling chemistry, often to tag 
large biomolecules like antibodies and nucleic acids.
1-2
 The most commonly used reactive 
fluorophores are designed to covalently label molecules containing a primary amine functional 
group such as lysine residues found in the peptides or protein structure. N-hydroxysuccinimidyl 
ester and isothiocyanate derivatives are among the most well characterized reactive fluorophores 
that are commercially available.
1
 Relatively early applications for reactive fluorophores include 
identifying serum components using labelled antibodies and visualizing cell structures (e.g., actin 
filaments) using indirect immunofluorescent staining.
2-4
 Fluorescently-labelled or conjugated 
antibodies continue to be used for various direct and indirect immunofluorescence techniques 
that have applications in fundamental research and diagnostic pathology.
2-6
 Although antibodies 
can be used as selective probes, small molecules are often more desirable for certain 
applications, including in vivo imaging, where the production of antibodies is not feasible, or 
where size, immunogenicity, or poor pharmacokinetic properties of antibodies becomes 
                                                 
*
This chapter represents a collection of work that is intended to be submitted for publication by multiple authors: 
Rhiannon L. Kamstra, Saedeh Dadgar, John Wigg, and Wely B. Floriano. Screening and experimental testing of 






 With the introduction of fluorophores that are active in the near-infrared spectral 
region, in vivo fluorescence imaging has become a viable functional technique for visualizing 
molecular composition of tissues and even dynamic intermolecular processes.
8-9
 Fluorescent 
probes can be designed that target specific receptors, that respond to environmental changes 
(e.g., pH), or that are activated by a specific enzyme.
10-13
 
 High-throughput virtual screening methods have been used to identify high-affinity 
ligands for a variety of protein targets.
14-19
 Hierarchical virtual ligand screening (HierVLS) is one 
protocol that uses a structure-based approach to screen large libraries of compounds against 
biologically relevant target structures, estimating a force-field binding energy for the complex. 
This method has been validated and used in previous investigations.
14, 20
 HierVLS, and other 
similar virtual screening methodologies have typically been used for identifying “hit” (lead) 
compounds intended for later development into therapeutic agents.
20-22
  
In this paper, we demonstrate that the creation and computational screening of 
fluorescently-labelled small molecule libraries is an efficient strategy for discovering target-
specific fluorescent molecular probes. We have created large virtual databases of easily 
synthesizable fluorescently-labelled small molecules and used virtual screening to identify 
ligands for two medically relevant protein targets. To demonstrate success, selected virtually 
identified ligands were synthesized and experimentally validated for predicted binding or non-
binding against their respective protein targets.  
Our validation screening and testing used a library of 1,153 primary amine-containing 
small molecules and its fluorescently labelled counterpart, which were screened against model 
structures of HPV protein E6 and botulinum neurotoxin subtype A (BoNT/A). Each protein 
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target has a publically available experimentally determined structure, is biologically relevant, 
and is the subject of ongoing investigation in our lab.  
E6 is a cancer-associated protein encoded by human papillomavirus (HPV) that causes 
ubiquitin-mediated degradation of a key tumor suppressor, p53, in infected cells.
23-25
 There is 
evidence that E6, and E6 variants, play a role in conferring a high-risk phenotype to certain HPV 
strains.
24-25
 Specific detection agents for E6 variants could provide valuable insight into tumor 
cell pathology in vivo, and could also be developed to complement existing diagnostic tools. 
Botulinum neurotoxin (BoNT), produced by Clostridium botulinum bacteria, is one of the most 
potent toxins, causes food-borne illness (botulism) and has the potential to be used as a 
biological weapon.
26-28
 BoNT is also the key component of several available therapeutic and 
cosmetic treatments (e.g., “Botox” by Allergan, Inc.).
29-30
 While some in vitro BoNT 
identification platforms exist, the current standard for confirmatory testing remains the “mouse 
lethality assay” (live mice are exposed to different concentrations of samples and observed), 
which is inefficient, takes several days to complete, and is associated with ethical concerns.
28-29
 
Particularly in light of its risk both in food products and as a bioterrorism threat, rapid in vitro 
tests for BoNT are currently in high demand.
27
 In an earlier investigation, a small molecule, 
paclitaxel was identified as a novel inhibitor of BoNT serotype A using virtual ligand screening 
(VLS), giving confidence that this target is amenable to targeting with this technique.
14
 
 The experimental validation of our fluorescent-labelling and screening protocol provides 
the rationale and framework for developing a high-throughput method for generating virtual 
fluorophore-ligand conjugates, to facilitate screening of large libraries of such compounds. We 
describe the development and implementation of a software-based script for parsing databases of 
small molecules containing appropriate reactive functional groups, and generating structures that 
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are conjugated to user-specified reactive fluorophores. These databases of novel fluorescent 
conjugates can be virtually screened against protein biomarkers for the rapid identification of 
target-specific fluorescent molecular probes. 
4.2. MATERIALS AND METHODS 
4.2.1. Preparation of the test libraries 
A library of 1,153 small molecules, each containing a single primary amine functional 
group, was used as a test virtual screening library. Compounds for this primary amines database 
(PAD) were downloaded from PubChem by drawing a basic primary amine structure and 
performing a structural similarity search. Lipinski’s “rule of 5” was used as a filter for drug-
likeness.
31-32
 Solvent and co-ion molecules were removed during processing, and entries 
containing atoms not parameterized by common force fields were excluded. The database was 
built and edited using MOE software.
33
 The Gasteiger method was used to assign partial charges 
and an energy minimization was conducted using MMFF94x force field.
34-35
 The database was 
then saved in a Tripos MOL2 format, with a total of 1,153 entries (supplementary information). 
 In addition, the PAD was computationally tagged with a Bodipy fluorophore (3-Bodipy-
propanoylaminocaproic acid, N-hydroxysuccinimide ester) by manually editing the structures. 
Conjugate structures were created according to the general reactivity scheme between primary 
amines and N-hydroxysuccinimidyl ester fluorophore derivatives that is described both in the 
literature
36-37
 and in the Molecular Probes Handbook.
1




Figure 4.2.1-1-N-hydroxysuccinimidyl ester (NHS ester) reactive fluorophores react with 
primary amines to form fluorophore/ligand conjugates that are linked via an amide bond. 
4.2.2. Protein structure preparation, VLS, and hit selection 
4.2.2. a) Protein structure preparation 
The experimental structure of the E6 protein (PDB Code: 2FK4) was obtained from the 
Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). Energy 
minimization was performed on the structure in MOE using the MMFF94x force field.
33, 35
 For 
molecular docking, the protein structure was converted into Biograf format using Babel and 
Biograf.v400fsm files were created using an in-house algorithm. YASARA software was used to 
generate a PDB file with hydrogens removed.
38-40
 A model protein structure for botulinum 
neurotoxin A (BoNT/A) was prepared previously.
14
 
4.2.2. b) Virtual ligand screening 
The BoNT/A and E6 structures were scanned for docking regions using the PASS 
method.
41
 Both structures were screened against the PAD with molecular docking and scoring 
performed according to the HierVLS approach.
20
 Docking and scoring of both PAD and Bodipy-
tagged PAD against BoNT/A and against E6 was carried out using the same methodology 
detailed in Dadgar et al (2013) (manuscript in preparation).
14
 For the Bodipy-tagged PAD, an 
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adjusted buried surface area cutoff of 30% (from 70%) was used to accommodate the increased 
average size of the molecules being docked. Good binding candidates for BoNT/A were selected 
based on whether they had a calculated binding affinity of one standard deviation higher than the 
mean binding score for the entire library at particular binding regions believed to be subtype-
selective (manuscript in preparation). Binding candidates for E6 were selected if they had a 
calculated binding energy below a threshold (-78.23kCal/mol) of two standard deviations below 
the mean binding score for the entire library at a particular binding region (-57.92kCal/mol). The 
scores of each selected binding candidate from the unlabelled ligand set were compared with 
those of their labelled counterparts. 
4.2.3. Source of chemicals for binding assays and fluorophore conjugation 
3-Bodipy-propanoylaminocaproic acid, N-hydroxysuccinimide ester (BODIPY® FL-X, 
hereafter abbreviated Bodipy-NHS; CAS 217190-09-5; Cat. B2527-40) and aspartame (CAS 
22839-47-0; Cat. A7462) were purchased from US Biological and LKT Laboratories Inc., 
respectively. BoNT/A LC was obtained from US Biological. O-Succinyl-L-homoserine (CAS 
1492-23-5) was purchased from Sigma Aldrich (Cat. S7129-25MG; 98% purity TLC). 
4.2.4. Synthesis and purity of fluorescent conjugates 
Detailed information on the synthesis and the purification of aspartame-Bodipy will be 
presented in a separate manuscript that is currently in preparation.
42
 Identity and purity of the 
isolated conjugate were confirmed using mass spectrometry and NMR respectively.
42
 
O-Succinyl-L-homoserine-Bodipy was synthesized by dissolving Bodipy-NHS (5 mg, x 
mmol), in 500 L of dimethylformamide (DMF). The reaction vial was placed, with stirring, in a 
water/ice bath at 0C followed by addition of O-succinyl-homoserine (2.7 mg) and triethylamine. 
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The reaction was flushed with argon and left to proceed for 30 minutes at 0C after which was 
allowed to stand at room temperature overnight. The reaction was quenched by addition of 
distilled water followed by extraction with ethyl acetate. The aqueous phase was frozen and 
sublimed using a freeze drier to yield the desired product (3 mg). The purity of the product was 
confirmed using TLC (5:1 dichloromethane:methanol) and the identity confirmed with liquid 
chromatography mass spectrometry(supplementary information).  
4.2.5. Fluorescence polarization overview 
Experimental validation of binding was performed using a fluorescence polarization 
assay. Fluorescence polarization assays rely on the principle that, when excited with polarized 
light, a static fluorophore will emit light that is polarized along the same plane. Depolarization of 
the light occurs in proportion to the amount of free rotation of the molecule in solution. 
Therefore, high polarization values are normally indicative of larger complexes that rotate less 
rapidly in solution, while low polarization indicates a relatively unrestrained fluorophore. 
Fluorescence polarization has been examined as a powerful and versatile method that can be 
used without complex separation or washing, does not require radiolabelled tracers and can be 
scaled for high-throughput applications.
43-45
 
4.2.6. BoNT/A fluorescence polarization assay 
 Aspartame-Bodipy was tested in a fluorescence polarization assay competing with 
unlabelled aspartame and unlabelled paclitaxel against BoNT/A light chain (LC). Paclitaxel has 
being shown to inhibit BoNT/A LC with an estimated IC50 of 5.2µM, with confirmed binding in 
a previous assay.
14
 In this experiment aspartame and paclitaxel were dissolved in assay buffer 
(20 mM HEPES buffer PH: 8.0, 0.1% Tween20, 0.3mM ZnCl2) and DMSO respectively at the 
concentration of 1µM. The concentration of aspartame-Bodipy was fixed at its EC50
42
 with a 
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fixed BoNT/ALC concentration of 2nM. Solvent (DMSO) controls were included. Samples were 
analyzed in triplicate using a 96-well black microplate (Costar) and a Synergy 4 Microplate 
Reader (Biotek, Inc) at 37ºC, read every 15 minutes for 2.5 hours. A full size 510 nm dichroic 
mirror was used with excitation and emission ranges of 440-505nm and 515-640 nm, 
respectively. The excitation and emission filters used were 485/20 nm and 528/20 nm, 
respectively. The filters and mirrors were used to ensure selective excitation of and emission 
reading for the Bodipy fluorophore used. Data visualization and non-linear regression analyses 
were performed using Prism.
46
 
4.2.7. Protein E6 intrinsic tryptophan fluorescence assay 
A change in intrinsic tryptophan fluorescence was used to measure the binding of O-
succinyl-L-homoserine to E6. Protein E6 contains only one tryptophan which is partially solvent 
accessible in the experimental structure of the unbound protein. Preliminary experiments with an 
E6-specific antibody (6F4) indicated that binding to E6 significantly quenched the emission 
associated to E6's single tryptophan. Unlabelled O-succinyl-L-homoserine was tested at 8 
concentrations (0.01, 0.1, 1, 3, 10, 25, 100, and 300 M) with a fixed concentration of protein E6 
(0.03mg/mL). O-succinyl-L-homoserine concentrations were diluted from a 1mM stock solution 
dissolved in deionized water. E6 protein was accurately measured from the stock concentration 
(0.201mg/mL). The assay was buffered to a pH of 7.5 using 20mM HEPES, 0.01% tween (v/v) 
and incubated to a temperature of 37C. Control wells were included for the unquenched protein 
using E6 (0.03mg/mL) in buffer alone and for each concentration of O-succinyl-L-homoserine. 
Samples were plated in triplicate and controls in duplicate in a 96-well black bottom microplate 
(Nunclon). The antibody 6F4 was used as a positive control at a concentration of 0.4ng/mL. 
Water, buffer, and sample were added first to all the wells in the microplate. E6 was added last to 
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sample or control wells, and the plate was incubated in the plate reader at 37°C. Emission spectra 
for each well were collected from 310nm-700nm at an excitation of 288nm. Fluorescence 
intensity was read using a probe height of 4mm, a 150sec delay between wells, and 20 reads per 
well, every 30 minutes for 60 minutes using a sensitivity value of 100 with Gen5 software 
(Biotek).  
4.2.8. Protein E6 fluorescence polarization assay 
O-Succinyl-L-homoserine-Bodipy was tested in a fluorescence polarization assay at three 
concentrations (1, 10, and 100M) with a fixed concentration of protein E6 (0.04mg/mL). The 
assay was buffered to a pH of 7.5 using 20mM HEPES, 0.01% tween (v/v) and incubated to a 
temperature of 37C. Control wells were included for the E6 protein without ligand and O-
Succinyl-L-homoserine-Bodipy in the absence of protein at each concentration tested. Samples 
were plated as single wells in a 96-well black bottom microplate (Nunclon).The experiment was 
conducted using a Synergy 4 Microplate Reader (Biotek) with a 485nm/20 excitation filter, 
528nm/20 emission filter, and a 510nm dichromatic mirror. Excitation and emission maxima for 
the labelled O-succinyl-L-homoserine were determined in preliminary experiments. 
Fluorescence polarization was read with a probe height of 4mm, a 350 sec delay between wells, 
and 40 reads per well. Data was collected every 15 minutes for 75 minutes using a sensitivity 
value of 65 using Gen5 software (Biotek). Fluorescence polarization values were calculated with 
background polarization values discounted. Data analysis, including a 4-parameter non-linear 





4.2.9. Fluorophore conjugation script and preparation of a labelled library 
We designed a script able to virtually conjugate reactive fluorophores with ligands 
possessing the correct functional group, according to a pre-defined reactivity scheme. Literature 
review was used to identify common reactivity schemes for commercially available reactive 
fluorophores. MOE’s scientific vector language (SVL) was chosen as the scripting environment 
due to the large number of available and relevant built-in functions and its suitability for large 
databases of small organic molecules.
33
 A SMARTS-based (http://www.daylight.com/) 
functional group identification algorithm, included as part of the MOE package, was used to 
recognize the functional groups involved in the fluorophore-ligand reaction. We designed this 
first version of the script to identify N-hydroxysuccinimidyl ester derivatives, and to label small 
molecules containing one primary amine functional group. The small molecule becomes labelled 
with an amide bond according to the scheme shown in Figure 4.2.1-1.
1
 The script accepts user-
specified MOE molecular database (MDB) files as input for both fluorophores and ligands. 
Molecules (either fluorophore or ligand) that do not contain the appropriate functional groups 
required for the fluorescent labelling reaction are skipped. Conjugate structures are outputted as 
entries to a new MOE database and assigned molecule names. The script was tested using small 
databases of fluorophores and ligands to ensure that it correctly matched the specified molecular 
patterns targeted by the script, and skipped molecules containing “decoy” functional groups 
(supplementary information). Using this script, the same base compound library containing n 




4.2.10. Base compound library for conjugation 
 The Molecular Libraries Small Molecule Repository (MLSMR) 
(https://mli.nih.gov/mli/compound-repository/mlsmr-compounds/) was selected as a source of 
molecular structures. There are three subsets each containing approximately 100,000 
compounds, as well as some additional structures, totaling over 400,000 compounds as of June 
2013.
47
 The Molecular Libraries Initiative describes the selection criteria for these compounds on 
their website (https://mli.nih.gov/mli/compound-repository/mlsmr-compounds/). PubChem 
offers structures for download in both 2D and 3D formats. PubChem generates 3D structures for 
all compounds matching a specific set of criteria (detailed on PubChem3D).
48
 One 3D conformer 
(if available) was downloaded in SDF format for each MLSMR compound from PubChem3D 
(http://pubchem.ncbi.nlm.nih.gov/), totaling 383,987 structures. The database was refined using 
MOE software (www.chemcomp.com/). SDF structures were loaded into MOE molecular 
databases and checked for counter ions and solvent molecules. Gasteiger atomic charges were 
calculated for each molecule.
34
 An energy minimization was performed on each database using 
the MMFF94x force field.
35
 Chirality was preserved for the downloaded structures. 
4.2.11. Generating a library of fluorescent conjugates. 
 The fluorescent labeling script was used to parse the database of MLSMR compounds 
from PubChem3D and conjugate all compounds containing one primary amine to one NHS-ester 
functionalized fluorophore. ATTO680 NHS-ester (PubChemCID 16218508) was used as the 
amine-reactive fluorophore in this case (Figure 4.2.11-1b). 
MOE software (www.chemcomp.com) was used for database preparation and refinement. 
Conjugates were outputted to a molecular database (MDB format) before being assigned 





were subjected to a conformational search using a built-in MOE function (“Conformational 
Import”), which is a high-throughput method for searching each molecules conformational 
space. Only one conformer was selected for each compound. Stochastic search failure and 
iteration limits of, respectively, 20 and 250 were used. Superposed conformations with an RMSD 
value of 0.15 or less were considered identical. Default constraints were used. 
 
Figure 4.2.11-1–Bodipy NHS ester (a) was the reactive fluorophore used for the experimental 
synthesis and testing of fluorescent small-molecule conjugates. ATTO680 NHS ester (b) is the 




4.3.1. Virtually screening fluorescence-labelled compound libraries is effective at 
identifying potential fluorescent probes 
A library of 1,153 primary amine-containing compounds (PAD) was screened using the 
HierVLS approach against two biologically relevant protein targets, botulinum toxin A 
(BoNT/A) and HPV 16 protein E6 (E6). Screening results for the unlabelled PAD against 
BoNT/A and E6 are shown in Figure 4.3.1-1 and Figure 4.3.1-3. The structures in this library 
were subsequently tagged with 3-Bodipy-propanoylaminocaproic acid, N-hydroxysuccinimide 
ester (Bodipy) by manually editing the structures to form an amide bond between primary amine 
nitrogen and the carbonyl carbon of the N-hydroxysuccinimidyl ester reactive group from the 
fluorophore (Figure 4.2.1-1). 
The Bodipy-labelled PAD was rescreened against both targets (Figure 4.3.1-2 and Figure 
4.3.1-4). The Bodipy fluorophore was chosen for virtual labeling because it is commercially 
available and suited for use with the available optical instruments in our laboratory. Aspartame 
and aspartame-Bodipy (Figure 4.3.1-5) both were predicted to bind to BoNT/A according to the 
binding threshold score used. O-Succinyl-L-homoserine was predicted to bind to E6 while its 
labelled counterpart, O-succinyl-L-homoserine-Bodipy (Figure 4.3.1-6) was not. These test cases 
were subject to experimental validation to confirm whether predicted binding or non-binding 





























A S P A R TA M E
 
Figure 4.3.1-1–Molecular docking results for unlabelled ligands against binding region 21 in 
BoNT/A LC. The solid and dotted lines represent mean and ±SD (standard deviation), 
respectively. Compounds scoring at or below the mean-SD threshold are expected to bind 
experimentally to the target. Aspartame was one of the ligands showing high predicted binding 
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Figure 4.3.1-2–Molecular docking results for Bodipy labelled ligands against binding region 21 
in BoNT/A LC. The solid and dotted lines represent mean and ±SD (standard deviation), 
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respectively. Aspartame-Bodipy (APM-BDP) scored close to one SD below the mean value 
(about 0.5kCal/mol higher than SD), and it is expected to bind to BoNT/A. 
 
Figure 4.3.1-3–Molecular docking results for unlabelled ligands against protein E6. The solid 
and dotted lines represent mean and ±2SD (standard deviation), respectively. O-Succiniyl-L-
homoserine scored below the threshold of the mean-2SD, and was selected for experimental 
testing against the target. 
 
Figure 4.3.1-4–Molecular docking results for Bodipy-labelled ligands against protein E6. The 
solid and dotted lines represent mean and ±2SD (standard deviation), respectively. O-Succiniyl-
L-homoserine-Bodipy scored relatively poorly, with a predicted binding affinity almost 2SD 
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worse than the average of all docked compounds and it is, hence, not expected to bind 
experimentally to E6. 
 
Figure 4.3.1-5–The structures of aspartame (top) and aspartame-Bodipy (bottom) used in this 
work. Bodipy-labelled aspartame was synthesized by conjugating aspartame to the amine 
reactive 3-Bodipy-propanoylaminocaproic acid, N-hydroxysuccinimide ester (Bodipy). Both 




Figure 4.3.1-6–The structures of O-succinyl-L-homoserine (top) and O-succinyl—L-
homoserine-Bodipy (bottom) used in this work. Bodipy-labelled O-succinyl-L-homoserine was 
synthesized by conjugating O-succinyl-L-homoserine to the amine reactive 3-Bodipy-
propanoylaminocaproic acid, N-hydroxysuccinimide ester (Bodipy). In this case, the unlabelled 
compound was predicted to bind to protein E6, whereas its labelled counterpart was not. 
4.3.2. In vitro testing of BoNT/A ligands 
The synthesized aspartame-Bodipy was tested in a fluorescence polarization binding 
assay to determine its binding affinity experimentally for the target, BoNT/A light chain (LC). It 
was also tested in competition with unlabelled paclitaxel, a confirmed BoNT/A inhibitor, and 
unlabelled aspartame. The data provided in Figure 4.3.2-1 shows that aspartame-Bodipy binds to 
BoNT/A-LC as the polarization value for aspartame-Bodipy in the presence of BoNT/A is 
significantly higher than the value associated to free aspartame-Bodipy (data not shown). The 
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data also indicates that aspartame and aspartame-Bodipy are competing for the same binding 
region on the BoNT/A-LC because the polarization value is decreased when experiments were 
performed with both aspartame and aspartame-Bodipy, compared to aspartame-Bodipy 

















































Figure 4.3.2-1-Fluorescence polarization binding assay using aspartame-Bodipy against 
BoNT/A-LC. The data related to unlabelled aspartame (APM) is shown in black whereas 
unlabelled paclitaxel (PAC) results are presented in square pattern. The addition of aspartame at 
1µM (left solid bar) reduces the fluorescence polarization associated with the binding of 
aspartame-Bodipy to BoNT/A (right solid bar), whereas the addition of paclitaxel (left checkered 
bar) increases the polarization of the corresponding aspartame-Bodipy reference (right checkered 
bar). Each labelled/unlabelled competition assay has its own reference because of the influence 
of DMSO on the fluorescence of labelled aspartame-Bodipy. The samples were run in triplicate 
at 37ºC and backgrounds were subtracted for each sample. 
Testing against unlabelled paclitaxel confirms the binding of aspartame-Bodipy to BoNT/A and 
indicates that aspartame-Bodipy and paclitaxel (a confirmed experimental inhibitor
14
 of 
BoNT/A-LC) bind to two distinct binding sites in BoNT/AL-C. Evidence for this hypothesis is 
provided by the increased polarization value in the sample containing both aspartame-Bodipy 
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and paclitaxel compared to the control containing aspartame-Bodipy alone. Binding of two 
ligands to distinct sites of BoNT/A-LC would enhance the size of the BoNT/A-LC complex and 
consequently increase the Fluorescence polarization value relative to that of BoNT/A-LC 
complexed with a single ligand. Each labelled/unlabelled competition assay had its own 
reference because of the influence of DMSO (necessary to dissolve paclitaxel) on the 
fluorescence of labelled aspartame-Bodipy. More details about the binding of aspartame-Bodipy 
to BoNT/A will be provided in a separate manuscript.
42
 
4.3.3. In vitro testing of E6 ligands 
 O-Succinyl-L-homoserine was tested for binding to E6 using an intrinsic tryptophan 
fluorescence assay. O-Succinyl-L-homoserine-Bodipy was synthesized and tested for binding 
against protein E6 using a fluorescence polarization-based assay. The unlabelled ligand was 
tested at 8 concentrations (0.01, 0.1, 1, 3, 10, 25, 100, and 300 M) while the labelled ligand was 
tested at three (1, 10,100 M) against a fixed concentration of protein. The results for the 
unlabelled and labelled compound are shown in Figure 4.3.3-1 and Figure 4.3.3-2 respectively. 
Unlabelled O-succinyl-L-homoserine exhibits a distinctive increase in tryptophan fluorescence 
relative to baseline control. An increase in signal is consistent with binding, as indicated by the 
positive (E6 antibody) control. No significant dose-dependency is observed at concentrations 
tested, however further characterization will be completed as part of a separate manuscript 




Figure 4.3.3-1-Change in intrinsic tryptophan fluorescence of E6 after 30 minutes incubation at 
37C buffered to a pH of 7.3 (20mM HEPES 7.3, 0.01% tween (v/v). Protein was held at a 
constant concentration of 0.03 mg/mL. 6F4 antibody was used as a positive control at a 
concentration of 0.4ng/mL. O-succinyl-L-homoserine concentration was varied (300µM-
0.01µM). The red line represents a 30% increase relative to baseline (no binding). 6F4 antibody, 
a positive control for binding, produces an increase in tryptophan fluorescence well over 30%. 
Labelled O-succinyl-L-homoserine-Bodipy polarization values after one hour do not differ 
substantially from control. This binding assay yielded no evidence that O-succinyl-L-
homoserine-Bodipy binds to protein E6, predicted by the low binding score of the docked 
compound relative to the threshold (Table 4.3.3-1). 
The experimental results (summarized in Table 4.3.3-1) for BoNT/A and E6 indicate that 
our VLS strategy accurately predicts whether a fluorescently-labelled compound will bind or not 
bind to the intended target protein. Moreover, the competition assay results suggest that this 





Figure 4.3.3-2-O-Succinyl-L-homoserine-Bodipy (100, 10, and 1M) and protein E6 
(0.04mg/mL) at 60 minutes. The experiment was conducted at a temperature of 37C and pH of 
7.5. Our results indicate that the O-Succinyl-Homoserine-Bodipy is not binding at any 
concentrations tested. Control wells containing protein as well as the O-Succinyl-L-homoserine-
Bodipy at all three concentrations dissolved in assay buffer were included in addition to the 
reaction wells. 
Table 4.3.3-1-A table outlining the predicted binding scores, expected experimental result, and 












Aspartame -82.20 -78.50 Yes Yes 
Aspartame-Bodipy -74.90 -75.31 Yes* Yes 
O-Succinyl-L-homoserine -45.62 -35.30 Yes Yes 
O-Succinyl-L-homoserine-
Bodipy 
-40.85 -56.50 No No 
*Aspartame-Bodipy scored close to the binding threshold. The labelled compound was expected 
to have some affinity based on previous tests that indicated that aspartame had high affinity, and 
based on an analysis of the predicted molecular interactions. Aspartame-Bodipy was selected as 
a candidate for testing based on these, and other practical criteria. 
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4.3.4. An efficient methodology for creating large libraries of fluorescence-labelled 
compound enables the use of VLS for probe discovery 
A script for conjugating reactive fluorophores to databases of small molecules 
(supporting information) was prepared using MOE’s scientific vector language (SVL). This 
script was able to distinguish between true candidates for conjugation and decoys (decoy 
database in supporting information). This script was used to virtually label a publically available 
database of base compounds with ATTO680 NHS ester (ATTO-TEC, Siegen, Germany; 
PubChemCID 16218508) according to the reactivity scheme shown in Figure 4.2.1-1. The 
resulting database contains 14,862 fluorescently-labelled compounds (supporting information) 
that would be suitable for VLS applications aiming at identifying targeted optical probes. The 
script can be easily modified to work with a different amine-reactive fluorophore for labelling. 
4.4. DISCUSSION AND CONCLUSIONS 
Significantly more extensive validation procedures have been previously described, 
which have given us confidence that HierVLS is a valid approach for screening small molecules 
for binding affinity.
20, 24-27
 However, this approach has not been used specifically for estimating 
the affinity of larger fluorophores and their small molecule conjugates. Our experimental results 
are in agreement with our computational predictions, which suggest that both unlabelled and 
labelled aspartame (aspartame and aspartame-Bodipy) have significant binding affinity for 
BoNT/A LC, and that O-succinyl-L-homoserine and its Bodipy conjugate will and will not bind 
to E6, respectively (summarized in Table 4.3.3-1).  
This demonstrates that a VLS approach, such as HierVLS, can be an appropriate tool for 
estimating the binding of conjugates of reactive fluorophores and appropriate small molecules to 
protein targets. As these screening approaches are designed to be high-throughput methods, 
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allowing for thousands of molecules to be screened against targets of interest, it is necessary to 
devise a method for generating fluorophore/ligand conjugates rapidly, from large databases of 
substructures. To realize this idea, we designed a script that recognizes the appropriate reactive 
groups associated with conjugating an NHS-ester fluorophore to ligands containing primary 
amines. The script was written using a vector-based programming language known as scientific 
vector language (SVL) used by MOE (www.chemcomp.com) software. This specific language 
and the additional pre-defined applications and functions found in MOE are particularly suited 
for high-throughput applications involving large molecular databases. The script is capable of 
handling a fluorophore database containing multiple entries, and will create conjugates for each 
fluorophore containing an NHS-ester functional group. The script will only create conjugates for 
NHS-ester/primary amine combinations, and will output all conjugates with a name based on the 
concatenated ligand and fluorophore names or IDs. In cases where either the fluorophore or 
ligand is missing the appropriate reactive group, the conjugation is skipped, and a message is 
written to a log file. A SMARTS-based connectivity algorithm, built into MOE, is used for 
recognizing the appropriate functional groups. A database of test compounds containing various 
functional groups was prepared and tested to ensure that functional groups other than primary 
amines were not being inadvertently recognized by the algorithm used. Particular attention was 
given to ensure that other nitrogen-containing functional groups, including nitriles, amides, 
nitrates, and secondary or tertiary amines were being correctly discriminated from primary 
amines. Compounds containing multiple primary amines were completely avoided by the script, 
with a message written to a log file to alert the user. While these compounds would likely react 
with NHS-esters, it would be necessary to determine which amine would be preferentially 
labelled. Moreover, experimental synthesis of these conjugates would likely require additional 
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purification or separation steps to ensure that the appropriate conjugate was being selected and 
used for testing. These practical considerations led to the decision to avoid compounds 
containing multiple reactive groups. This version of the script is designed to be a basic 
implementation of our idea, which can be expanded in later versions to include other types of 
reactive fluorophores, and exclude entries containing undesirable molecular features such as 
groups which could confer toxicity or that commonly participate in side reactions with reactive 
fluorophores. 
Once tested, the script was deemed adequate for the virtual labeling of large databases of 
small molecules with reactive NHS-ester fluorophores. We generated a large labelled database 
using publically available small molecule structures and one NHS-ester fluorophore, for later use 
in virtual screening applications.[1-(3-Carboxypropyl)-11-ethyl-2,2-dimethyl-1,8,9,10-
tetrahydro-2H-dipyrido[3,2-b:2',3'-i]phenoxazin-11-ium-4-yl]methanesulfonate, marketed as 
ATTO680 (ATTO-TEC, Siegen, Germany) is the fluorophore moiety that was chosen for this 
database. ATTO680 is a relatively hydrophilic commercial fluorophore that fluoresces in the red 
region, which is more appropriate for cell-based in vitro applications, and possibly in vivo 
applications.
49
 In comparisons with other popular fluorophore series including AlexaFluor® 
((Molecular Probes Inc.) and BODIPY® (Molecular Probes Inc.), ATTO680 exhibits among the 
best signal to noise ratios for aqueous applications.
49
 ATTO680 has been shown to be an 
appropriate choice for both steady-state and time-resolved fluorescence applications, which 
would enhance the experimental utility and versatility of any fluorescent conjugates bearing this 
moiety.
49
 ATTO680 NHS-ester (PubChemCID 16218508) was used as the amine-reactive 
fluorophore (Figure 4.2.11-1b). Its structure is publically available and does not contain exotic 
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atoms that could interfere with VLS. While ATTO680 was chosen for generating an in-house 
tagged library, the script can easily work other NHS-ester fluorophores. 
The Molecular Libraries Small Molecule Repository (MLSMR) 
(https://mli.nih.gov/mli/compound-repository/mlsmr-compounds/) was selected as a source of 
small molecule structures due to its public availability and its suitability for probe development. 
MLSMR is a collection of small molecules accessible for the purposes of high-throughput 
screening for biomedical applications, maintained as a part of the Molecular Libraries Initiative 
(MLI). The MLI is an NIH-funded programs which “offers public sector biomedical researchers 
access to the large-scale screening capacity necessary to identify small molecules that can be 
optimized as chemical probes to study the functions of genes, cells, and biochemical pathways” 
(http://commonfund.nih.gov/Molecularlibraries/overview.aspx). The MLSMR restricts entries 
based on numerous criteria with specific considerations given to the suitability of these 
compounds for high-throughput experimental screening. For example, minimum water solubility 
thresholds and minimum vendor amounts and purity were considered. The database is designed 
to retain a high level of diversity while implementing minimal restrictions on the types of 
chemical structures.
47
 These characteristics may facilitate the translation of future screening 
efforts to experimental work.  
The development of a high-throughput methodology for virtually generating structures of 
putative fluorescently labelled conjugates is an important step in facilitating the computational 
identification and/or design of these types of molecules as potential molecular probes. However, 
there are several limitations and future challenges that must be considered. Firstly, our 
implementation of this idea is quite rudimentary, and it’s suited for one specific reactive 
fluorophore class. It would be feasible to expand this simple script in the future such that a more 
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complex piece of software could be developed that would enable screening of other reactive 
fluorophores, such as isothiocyanates and maleimides, thus expanding the scope of possible 
conjugation reactions. Additional criteria could also be applied such that the conjugates produced 
are most likely to be feasible experimentally, by ignoring molecules containing functional groups 
that might interfere with the labeling process, for example. While both small-molecule 
conjugates tested in this case were readily synthesized in the laboratory using standard 
techniques, it would be ideal to come up with a range of molecular descriptors that would 
prioritize molecules based on their predicted reactivity for labeling. Fluorophore-ligand 
conjugates are also typically quite large, and thus, have many conformational degrees of 
freedom. It would be important that, in any screening efforts using these molecules, this issue 
would be accounted for by using one or more conformational sampling or simulation techniques, 
such as molecular dynamics simulations. 
The final fluorescently-labelled database numbers 14,862 compounds, each tagged with 
the ATTO680 fluorophore. This library is highly suitable for VLS efforts seeking to identify 
fluorescent probes for biomarkers. While the use of fluorescent labeling technology has been 
highlighted by large biomolecule labeling, there is the demand for labelled small molecules for 
specific in vitro and in vivo applications, the discovery of which can be computationally aided 
through such methods. 
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Identifying potential selective fluorescent probes for cancer-
associated protein carbonic anhydrase IX using a computational 
approach 
5.1. INTRODUCTION 
Carbonic anhydrase IX (CAIX) is a protein that is expressed in several tumour types, 
including cervical cancer, and is rarely expressed in healthy tissues outside of the gastrointestinal 
tract.
1
 Carbonic anhydrases are a family of proteins that catalyze the reversible hydration of 
carbon dioxide. CAIX activity and expression are associated with tumour-related hypoxia. There 
is increasing evidence that CAIX activity in tumours correlates significantly with increased 
invasiveness, increased likelihood of metastasis, and poor overall survival, suggesting that CAIX 
expression is an important indicator for prognostically relevant tumour pathology.
2-3
 
A reliable method of measuring of CAIX expression in vivo through imaging could 
become an important tool for assessing the cellular and organism-level response to novel tumour 
treatments during pre-clinical research. Optically active probes could be used to selectively 
image changes in CAIX expression throughout a course of treatment, either in vitro or in vivo. 
However, CAIX-based assessments of treatment efficacy should not be biased by any effects the 
probe may have on the activity of CAIX or other CA isoforms. Thus, an ideal probe for tumour 
monitoring should have high affinity and specificity for the CAIX isoform and should not 
interfere with its normal function.  
 
2 
Fluorescence-based imaging techniques are improving and may be used to obtain images 
through shallow tissue depths of up to a few centimeters.
4
 Range is improved and interference 
from autofluorescence is minimized by utilizing fluorescent moieties that emit light in the near-
infrared (NIR) range of the electromagnetic spectrum.
4
 NIR wavelengths are poorly absorbed by 
water and hemoglobin, and therefore, use of NIR-emitting probes improves signal penetration 
and reduce changes in signal due to physiological composition.
4
 Relatively few available 
molecules possess the desired optical qualities, making it unlikely to identify a small molecule 
intrinsically suitable for imaging, while also conferring strong affinity and selectivity for the 
desired target, CAIX. However, it is possible to conjugate a suitable reactive dye to a small 
molecule containing specific chemical functional groups to create a target-specific fluorescent 
probe. 
In this paper, we propose 20 fluorescent CAIX probe candidates for experimental 
validation. Candidates were selected from a virtual database of 20,860 compounds, which were 
either fluorescently-labelled or had published evidence of intrinsic fluorescence. The database 
was screened against a CAIX model using hierarchical virtual ligand screening (HierVLS), 
which combines a force field-based approach with a hierarchical framework to maximize 
efficiency for high-throughput screening applications.
5
 Previously published experimental data 
on CAIX inhibitors was used to validate the methodology used.
6
 Available sequence information 
for other CA isoforms was used to prioritize candidates based on the estimated “uniqueness” of 
each binding site. The extensively studied structure and mechanism of carbonic anhydrases, in 
addition to the availability of a crystal structure for CAIX
7





5.2. METHODS AND PROCEDURES 
5.2.1. Preparation of the CAIX model structure 
The only available experimental structure of the target protein, carbonic anhydrase IX 
(CAIX), was downloaded from the RCSB Protein Data Bank (www.rcsb.com). This structure 
(PDB Code: 3IAI) was obtained using X-ray diffraction at a resolution of 2.20Å.
7
 The biological 
assemblies associated with PDB:3IAI are proposed homodimers. Chain A, corresponding to one 
CAIX monomer, was selected for modeling. Editing and structure quality checking of the protein 
structure were performed using the programs YASARA (www.yasara.org) and/or MOE 
(www.chemcomp.com), unless otherwise noted. Solvent molecules, co-crystallized ligands 
(except for Zn
2+
) and covalently-linked carbohydrate moieties were removed from the structure. 
A mutated residue in the crystal structure (Cys41Ser) was replaced with its wild-type amino acid 
(Cys41). Missing atoms and side chains were identified and corrected. The CAIX model 
structure was then assigned CHARMM22 atomic charges and subjected to 2,000 steps of 
conjugate-gradient minimization using the Dreiding force field.
8-9
 Model coordinates are 
included as supplementary material. 




 were used to 
check the quality of the resulting modeled structure (complete results detailed in supplementary 
material). MOE software was used to generate a Ramachandran plot (Figure 5.3.1-1) and figures 
of the model structure (Figure 5.3.1-2 to Figure 5.3.2-2). The CAIX model structure was 
compared to the experimental structure (PDB: 3IAI) to ensure that significant conformational 
changes were not induced by the energy minimization procedure. The model structure was 
aligned and superposed with 3IAI (Chain A) and all-atom and C-α RMSDs were calculated. This 
 
4 
procedure provided a visual confirmation that residues proximal to the active site had retained 
their relative positions after modeling.  
5.2.2. Multiple sequence alignment and binding site comparison 
The amino acid sequences of 23 known CA isoforms (supplementary material) were 
obtained from NCBI GenBank (http://www.ncbi.nlm.nih.gov/genbank/). A multiple sequence 
alignment was constructed using ClustalX 2.1
12
 using the Gonnet matrix series, gap opening: 10, 
gap extension: 0.2, delay divergent sequences: 30%. 
Binding pockets within the CAIX model structure were identified using PASS, which is a 
freely available algorithm that relies on geometry to identify potential sites.
13
 Binding site 
centers were used to construct a graphical representation of each binding site within the model 
structure using MOE software. Residues with atoms between 0-5Å of each predicted site center 
were identified, and their position was annotated with respect to the multiple sequence alignment 
of CA isoforms. Percentage of amino acid identity to CAIX at each marked position was 
determined, and each binding site was scored according to its uniqueness to the CAIX isoform 
(Table 5.3.2-1). 
5.2.3. Known inhibitors library for structure validation 
A literature review was conducted to identify 32 small molecule inhibitors of CAIX with 
reported Ki values in the 14-305 nM range.
6
 Structures for these molecules were obtained either 
from PubChem (http://pubchem.ncbi.nlm.nih.gov/), BindingDB (www.bindingDB.org), or were 
constructed using MOE software (www.chemcomp.com) according to the structure reported in 
the literature. Inhibitor structures were assigned Gasteiger atomic charges and energy-minimized 





5.2.4. Decoy library for virtual screening 
A decoy library of chemical compounds was created for validation purposes. No 
available decoy databases were found for carbonic anhydrase IX in two commonly used decoy 
repositories, DUD (http://dud.docking.org/) and DUDE (http://dude.docking.org/). Several target 
proteins that are structurally dissimilar to each other and that are also unrelated in function and 
structure to carbonic anhydrase were selected and the structures of known high-affinity ligands 
for these targets were downloaded from a publicly available repository of ligand structures and 
binding data known as BindingDB (www.bindingDB.org). Our assumption is that high affinity 
ligands for targets that are dissimilar to CAIX, will be unlikely to have any significant affinity 
for CAIX, and would therefore be suitable as decoy molecules. Ligands for several different 
“targets” were used as decoys to help ensure some chemical diversity in the decoy library, and 
not bias the library toward a particular chemical substructure. Specific inhibitors with Ki or IC50 
values below 10nM were obtained for the following targets (number of inhibitors in 
parentheses): neuraminidase (25), metabotropic glutamate receptor isoforms 1-8 (213), 
monoamine oxidase A and B (199), VEGFR (44), and EphB4 (39).
16-19
 3D structures for these 
decoy ligands were generated using MOE (www.chemcomp.com) from available 2D SDF 
structures or canonical SMILES (simplified molecular-input line-entry system) strings. 
Redundant molecules were eliminated yielding a decoy library of 478 unique entries. Decoys 
were cross-referenced for any documented activity against any carbonic anhydrase isoform in 
secondary BindingDB queries. Various chemical properties were calculated for the decoy set and 
compared to those of the inhibitor library in order to evaluate whether the decoys sufficiently 
represent the properties of the inhibitor library. Molecule structure files were prepared for 
screening by removing counter ions and solvent molecules and eliminating molecules containing 
 
6 
unparameterized atoms. Atoms were assigned Gasteiger charges and ligand structures were 
energy-minimized using the MMFF94x force-field.
14-15
 Various molecular descriptors were 
calculated for both the inhibitor and decoy set using MOE software in order to compare the 
distribution of properties between the groups. 
5.2.5. Validation Screening 
The combined library of 460 decoys and 32 known CAIX inhibitors was computationally 
screened against the 3D model of CAIX using PASS for binding site identification and HierVLS 
for molecular docking and force field-based scoring. PASS is a rapid and efficient program that 
uses a geometry-based algorithm to identify putative binding pockets based their shape, size, and 
depth relative to the protein surface.
13
 It is freely available and generates output that is generally 
compatible with applications used in later steps. HierVLS is a hierarchical approach to virtual 
ligand screening that tests the largest number of bound conformations of each ligand using the 
least computationally expensive methods, and proceeds to use more computational resources to 
obtain more accurate predictions of binding energy for the most promising conformers.
5
 
Screening was initiated using a graphical user interface (GUI) known as Cassandra, and 
calculations were run using the SHARCNET high-performance computing network 
(www.sharcnet.ca).
20
 For each ligand, a maximum number of 10,000 docked conformations were 
generated in level 0 (coarse-grain conformational search), with the 1500 best conformers passed 
to the filter step. Conformations were eliminated by the filter if they had less than 70% buried 
surface area. 150 conformations per ligand were passed from the filter step through to level 1 
(protein-fixed minimization). The best 3 docked conformations for each ligand were subject to 
an all-atoms minimization (level 2). Final raw binding scores (kcal/mol) consider the desolvation 
effects of the protein/ligand complex by applying the analytical volume generalized Borne 
 
7 
solvation model to the complex, and the protein and ligand alone. The steps and parameters of 
the HierVLS docking and scoring scheme have been described previously.
5
 A complete list of 
HierVLS parameters used for this experiment is included in the supplementary material. Raw 
binding scores were collected for each ligand docked to each of the 4 identified binding sites. 
Three separate score-adjustment schemes were applied to the raw scores. Raw binding scores 
were adjusted to give site-specific propensity relative to other binding sites using two separate 
in-house algorithms. In a separate step, raw binding scores for each ligand in all regions were 
subjected to principal components analysis (PCA) using PAST statistical software 
(http://folk.uio.no/ohammer/past/). Ligands without binding data for any of the 4 sites (due to 
failing the buried surface cut-off filter) were excluded from analysis (18 decoys), leaving 460 
and 32 scored decoys and true positives, respectively. PCA was performed using a correlation 
matrix type with singular value decomposition (SVD) enabled and iterative imputation to handle 
missing values with the following other parameters: Boot N=0, Jolliffe cut-off=0.7. An analysis 
of the test characteristics for each score-adjustment scheme (raw scores, in-house algorithms, and 
PCA) was performed using PRISM
21
 and Microsoft Excel 2010. 
5.2.6. CAIX Virtual Screening 
The CAIX model was screened against two compound libraries. One library contains 
14,862 primary-amine containing compounds that were identified from Molecular Libraries 
Initiative Small Molecule Repository (MLSMR) and tagged virtually with Atto680 NHS-ester 
(database available with supplementary material). Atto680 is a near-IR fluorophore that is 
commercially available in a reactive N-hydroxysuccinimidyl ester form.
22
 The preparation of this 
database is described in another manuscript (Chapter 4). An additional subset of the MLSMR, 
was identified using PubChem BioAssay data. Molecules with reported activity in a published 
 
8 
series of high-throughput fluorescence assays
19
 were selected, totaling 5,998 compounds. The 
overall number of compounds screened against CAIX was 20,860. These databases and 
associated PubChemBioAssayIDs are included with supplementary material. The parameters 
used for screening were identical to those used during the validation procedure with the 
exception of the buried surface area cut-off for docked ligands, which was adjusted from 70% to 
40% when screening the fluorescently-labelled compounds to reflect their larger overall size. 
“Hit” candidates were identified based on the scoring scheme and binding thresholds that 
best performed during the validation step. Best conformers for the binding candidates were 
examined for favourable protein-ligand interactions (using MOE software). Candidates were also 
assessed for binding site preference by comparing raw scores between specific sites relative to 
each binding site’s mean scores and score standard deviation for that database. 
5.3. RESULTS AND DISCUSSION 
5.3.1. Preparation of the CAIX model structure 
A CAIX model structure was prepared from the 3IAI PDB structure. A Ramachandran 
plot was generated (Figure 5.3.1-1), and PROCHECK/WHATCHECK quality analyses 




Figure 5.3.1-1–A Ramachandran plot for the CAIX model structure (generated using MOE 
software). 
Psi-phi bond angles (Ramachandran) appeared to be consistent with a reasonable structure. 
Quality analyses were used to check to ensure that missing sidechains (and atoms) had been 
added during the modelling process, and that the starting and final structures did not have any 
serious structural abnormalities. The model was compared to the crystal structure by calculating 
the all-atoms RMSD which was found to be 0.354Å. When a c-alpha RMSD was performed, 
results were similar, and showed that less than 5 residues had αC-alpha RMSD greater than 2 
standard deviations from the mean RMSD (0.48Å was the maximum). Combined with the 
quality results, these comparisons gave us confidence that our model would be representative of 




Figure 5.3.1-2 – A cartoon representation of the CAIX model structure with the zinc cation 
shown in the center of a large binding cavity. 
Four binding sites were identified using PASS. Sites 1, 3, and 4 are shown as surfaces Figure 
5.3.2-1. Site 2 corresponds to the catalytic site (Zn
2+
 shown) and has the most buried surface of 
the four sites (Figure 5.3.2-2). 
5.3.2. Multiple sequence alignment and binding site comparison 
A multiple sequence alignment of 23 human isoforms was performed (provided in 
supplemental material). All residues within 5Å of each binding site of CAIX were compared for 
identity using the sequence alignment. The distances from the center of each binding site to the 
catalytic site (site 2) were also calculated. A summary of % homology and distance to the 
catalytic site for all binding sites is shown in Table 5.3.2-1. Based on this analysis, hits will be 
prioritized for experimental testing if they show selectivity for sites 1 or 3, which show the least 




Figure 5.3.2-1 – A surface representation of the CAIX model with the centers of sites 1, 3, and 4 
(1 would be the most preferable for binding, 3 the second most, and 4
th
, the least) shown as blue 
spheres. Surface colours represent hydrophilic (pink), hydrophobic (green) and neutral (white) 
regions. 
 
Figure 5.3.2-2 – A surface representation of the CAIX model showing binding site 2 (blue 
sphere representing its center), which represents the catalytic site. The zinc cation is shown as a 




Table 5.3.2-1 – The % sequence identity for residues within 5Å of each binding region to the 
sequence alignment of 23 CA isoforms is shown, along with the distance from the catalytic site 
(2). 
Region Identity (%) Distance from Catalytic Site (Å) 
1 14.6 21.28 
2 67.2 n/a 
3 17.4 13.76 
4 29.2 11.68 
 
5.3.3. Validation screening 
Four scoring schemes were assessed using a test set of 32 known CAIX inhibitors
6
 and 
460 decoys. Raw (force field-based) scores, two different holistic scores (adjusted for site-
specific propensity using different in-house algorithms), and scores given by a principal 
components analysis (PCA) were analyzed. Raw scores from region 2, which corresponds to the 
active site, were used because 32 inhibitors in the validation site bind to the active-site of the 
protein and, hence, their binding affinities for that site may correlate with experimental values. 
For the PCA scoring scheme, the first principal component (PC1) was used because it carries the 
most variance (65.96%) in the calculated binding affinity it represents. PCA was the only scheme 
to improve the discrimination between true binders and decoys relative to the raw scores.  
Figure 5.3.3-1 represents the sensitivity and specificity of the PCA scheme relative to the 
raw scoring scheme using a receiver operating curve (ROC). The area under the curve (AUC) 
was calculated for all scoring methods. AUC is a commonly used metric for evaluating 
diagnostic test performance, and signifies the probability that a random true positive will be 
 
13 
ranked better than a random true negative.
23
 The PCA scoring scheme performed the best, with 
an AUC of 92%.  
 
Figure 5.3.3-1 – The ROC curves for the PCA and raw (force field-based) scoring schemes used 
for the validation screen of CAIX. The area under each curve (AUC) is shown for each scoring 
scheme in parentheses. 
A frequency histogram of PC1 scores for both decoys and true positives is shown in 
Figure 5.3.3-2a. It is evident from this distribution that the PC1 scores for true positives lay 
toward the negative side of the distribution. In order to choose a threshold below which 
candidates will be selected for experimental testing, the positive predictive value (PPV) of the 
PCA scheme was examined. The PPV signifies the probability that a compound with a score that 
is better than the threshold will be a true binder (Equation 5.3.3-1). The PPV depends on the 
sensitivity and specificity of the selected threshold, as well as the prevalence of true positives in 
the database being screened. With respect to the ROC curve, increasing sensitivity and 
specificity values are associated with a shift in the curve toward the topmost and leftmost parts of 
the graph, respectively. For our purposes, we were most interested in enhancing the PPV, 
because we would like to increase the probability that compounds selected for testing will have 




Figure 5.3.3-2 – The PCA scoring scheme was selected for library screening. A frequency 
histogram of scores for decoys and true positives in the validation library are shown in (a). The 
specificity, sensitivity, and positive predictive value (PPV) of the PCA scheme determined using 
the validation library are shown in (b). The highest possible PPV value, assuming a 1% 
prevalence of hits in a database, occurs at a threshold of -3.317. Relatively few compounds in the 
validation library scored below the threshold value of -3.317 (c). 
Equation 5.3.3-1 – The positive predictive value (PPV) is the fraction of all positives, true (TP) 
and false (FP), that are true positives. 

PPVTP (TPFP) 
It is acceptable if our selected threshold has a relatively low sensitivity, as it is 
unnecessary for us to successfully identify all true positives within a database. In this context it 
was ideal to improve the discriminatory ability of our threshold such that few false negatives 
were chosen. Alternatively, if we believed that there were very few true positives in a database, 
or if we were using this type of screening for another application where identifying all actives 
were a priority, we could adjust the threshold for better sensitivity. Assuming a prevalence of 
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true positives of 1% in a hypothetical database, we graphed the PPV across a range of scoring 
thresholds, also including associated specificity and sensitivity values (Figure 5.3.3-2b).The PC1 
score threshold that gave the best PPV was -3.317. At this threshold, the PPV would be 10.63% 
for a database containing 1% hits. The corresponding sensitivity and specificity for this threshold 
are 28.13% and 97.61% respectively. Figure 5.3.3-2c shows a distribution of the PC1 scores for 
the validation set, with decoys and true positives shown with respect to the chosen threshold. The 
PPV for this scoring scheme suggests that in future screening experiments at least 10-15 top 
candidates should be identified for experimental testing to increase the likelihood of identifying a 
true binder. The enrichment factor (EF) is a metric commonly used to describe the performance 
of virtual screening methods. EF gives the ratio of true positives detected in the top x% of scored 
compounds to the number that would have been expected based on random selection: 
Equation 5.3.3-2 – The enrichment factor (EF) is given by the ratio of the number of hits (n) 
found above the threshold (top x %) to the expected number of hits, the proportion (P) of overall 
hits in the database multiplied by the number of compounds overall (N) above the threshold (top 
x %). 
 
An enrichment factor of 1 would indicate that the method is no better at selecting true 
positives than random selection. The enrichment factors are given for the chosen threshold (PC1 
score < -3.317) as well as for the top 2, 5, 10, and 20% of scored compounds in the validation 
library in Figure 5.3.3-3. This figure also displays the true positives (hits) identified at each 
threshold as a proportion of the total number of true positives (N=32) in the validation library. 
The threshold score chosen using ROC analyses (PC1 score <-3.317) gave the best enrichment 




PhitsN in top x%
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among compounds selected using the chosen threshold is increased relative to random selection 
within the overall database by a factor of almost 7. When systematically assessed for 
performance with test ligand sets across multiple targets, 11 different docking programs were 
shown to have enrichment factors between 0.0 and 10.0 for the top 10% of their databases.
24
 For 
the PCA scoring scheme, EF=5.65 for the top 10% of PCA scores, indicating that our observed 
EFs agree reasonably well with values reported for other screening protocols.  
These analyses should be considered with some uncertainty, as they are based on a 
relatively small validation library. This library was also necessarily composed of compounds 
targeting only one site, the active site, of the protein. Nonetheless, when binding scores vary 
continuously on a normal distribution, it can be very difficult to decide upon a binary threshold. 
The use of a validation set to estimate the predictive value of our scoring scheme is important for 
justifying a threshold value in subsequent tests, despite this uncertainty. Comparison of 
enrichment factors with those obtained in the literature for other docking and scoring methods 
gives us confidence that our scoring scheme has significant predictive value for selecting binding 




Figure 5.3.3-3 – The number of true positives found (N) using each indicated threshold (i.e., top 
x% of validation library screened) as a fraction of the total number of true positives present in 
the validation library (N=32). Enrichment factors (EFs) were calculated for each of the indicated 
threshold values and shown in tabulated format. The PC1 score threshold that was selected using 
ROC analysis gave the highest EF value, 6.92. 
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5.3.4. CAIX Screening 
A total of 20,860 compounds were screened against the CAIX model. Scores were 
adjusted using principal components analysis (PCA) which was determined in the previous step 
to be the preferred scoring scheme. A PC1 score threshold of -3.317 was used, below which 
molecules were considered candidates for binding. A distribution of the PC1 scores for 
molecules screened is shown in Figure 5.3.4-1.  
 
Figure 5.3.4-1 – A distribution of scores for molecules screened in the Atto680-tagged (blue) 
and Fluorescent MLSMR (red) databases. The threshold PC1 score -3.317 is marked. 
Table 5.3.4-1 summarizes 20 top scoring binding candidates for both the Atto680-tagged and 
Fluorescent MLSMR libraries. For each of these candidates, best scoring conformers from each 
binding site were examined, and site-specific raw scores compared. Scores were examined for 
number of standard deviations above the mean score for that site (in a particular library). Site 1 
had been selected previously as the most preferred binding site based on lack of homology 
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between other isoforms, and distance from catalytic site. The site specific scores relative to the 
mean are summarized in Table 5.3.4-2 and Table 5.3.4-3 for the best 5 compounds in each of the 
libraries. Each of these 5 ligands (or in the case of the Atto680-tagged library, the parent 
unlabelled primary amine) is shown in Table 5.3.4-4 and Table 5.3.4-5. 
Table 5.3.4-1 – Top 20 ranked compounds screened from both the Atto680-tagged and 
Fluorescent MLSMR databases. 
Fluorescent MLSMR Atto680 MLSMR 
PubChem CID PC1 Score PubChem CID* PC1 Score 
CID652931 -9.927 CID16746148 -10.887 
CID5154 -7.674 CID5939529 -9.614 
CID1256741 -7.576 CID666466 -9.445 
CID2999504 -7.538 CID5939530 -9.232 
CID665212 -7.441 CID20846957 -9.059 
CID854591 -6.975 CID666309 -8.933 
CID446849 -6.293 CID667134 -8.915 
CID649288 -6.104 CID665941 -8.498 
CID2368420 -5.351 CID535684 -8.437 
CID441975 -5.330 CID666821 -8.378 
CID656158 -5.323 CID3153996 -8.259 
CID648233 -5.310 CID1939105 -8.229 
CID5389398 -5.261 CID3104972 -8.201 
CID662206 -5.255 CID25163910 -8.165 
CID3243178 -5.243 CID6916824 -7.989 
CID1301431 -5.217 CID8795 -7.982 
CID666072 -5.152 CID666424 -7.976 
CID4849 -5.097 CID1491128 -7.952 
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CID16231 -5.091 CID667344 -7.913 
CID5546 -5.057 CID1853629 -7.852 
*PubChemCID given for parent compound of Atto680-tagged conjugate. 
Table 5.3.4-2 – Best 5 compounds with suggested binding preference for region 1 from the 
Fluorescent MLSMR database. Raw scores were examined relative to mean, and expressed as 




 N x Std. Dev. Above Mean 
Raw Site 1 Score 
 N x Std. Dev. Above Mean Raw 
Site2 Score 
CID652931 -60.8793 3.7 0.3 
CID5154 -56.8195 3.1 0.5 
CID1256741 -51.6917 2.3 -0.5 
CID2999504 -50.746 2.2 -0.7 
CID665212 -51.671 2.3 -0.4 
 
Table 5.3.4-3 – Best 5 compounds with suggested binding preference for region 1 from the 
Atto680-tagged MLSMR database. Raw scores were examined relative to mean, and expressed 




 N x Std. Dev. Above Mean 
Raw Site 1 Score* 
 N x Std. Dev. Above Mean 
Raw Site 2 Score 
CID667134 -8.915 6.6 5.3 
CID535684 -8.437 7.8 4.6 
CID666821 -8.378 5.6 4.4 
CID3104972 -8.201 5.9 2.8 







Table 5.3.4-4 – Chemical structures of the top 5 scoring Fluorescent MLSMR compounds. 





















Table 5.3.4-5 – Base chemical structures of the top 5 scoring Atto680-tagged MLSMR 
compounds. 













By using a test-set validated scoring scheme, and additional ranking criteria, we have 
identified several promising probe candidates for experimental testing against CAIX. We predict 
that the post-screening criteria used for ranking of these compounds will impart additional 
selectivity against CAIX isoforms than would have otherwise been present.  
We are very confident about the ability of our methodology to predict the true binding of 
fluorescent probes to CAIX. However, there remain several challenges in our study. CAIX 
activity is Zn-dependent, and the orientation of the active site relative to the Zn
2+ 
ion is crucial 
both for catalysis and inhibition. While we ensured that Zn orientation within the active site was 
not significantly altered, it is still possible that small changes in the active site orientation due to 
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minimization and modeling procedures may have affected the accuracy of our model. Zinc and 
other metal ions are typically handled poorly by force field-based approaches, which likely 
affected the accuracy of our scores. We provided estimates of binding site homology based on a 
multiple sequence alignment of all human CA isoforms and predicted the preferential site of 
binding for each ligand based on site-specific scores from HierVLS. The scoring method for 
ranking compounds, PCA of raw scores, does not retain information about binding site 
selectivity. This method is useful as a rough approximation of the amount of conservation 
between isoforms, however, it does not account for 3D structural variation. An alternate 
approach could include developing homology models for the most common isoforms, and cross-
screening promising candidates against them in order to estimate isoform specificity. Such an 
approach would require additional time and computational resources, but would be 
recommended as part of a subsequent investigation prior to experimental testing.  
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Identification and in vitro testing of potential EphB4 kinase 
modulators  
6.1. INTRODUCTION 
 EphB4 receptor tyrosine kinase is frequently overexpressed in many types of cancer, 
including breast, gastric, and colon carcinoma.
1-3
 Disrupting EphB4 signalling may be a 
chemotherapeutic approach that retards tumor growth by inhibiting vessel development, 
therefore depriving cancer cells of nutrients.
1, 4-5
 Several small-molecule inhibitors of the EphB4 
kinase domain have been reported
6-14
, but there has yet to be a selective EphB4 kinase inhibitor 
approved for clinical treatment. However, previous success in targeting tyrosine kinases 
therapeutically suggests that this approach is warranted in biologically relevant proteins of this 
family.
15
 Novel selective EphB4 kinase inhibitors could represent important lead compounds to 
be further optimized for use as chemotherapeutic drugs. EphB4-specific molecules could also 
have potential roles in cancer diagnosis and treatment. The involvement of EphB4 expression in 
tumour growth and cancer prognosis makes it a potentially useful biomarker for functional 
imaging modalities like positron-emission tomography (PET).
16
 Probes labelled with positron-
emitting isotopes could be used with PET to visualize patient tissues expressing high levels of 
EphB4 indicating the presence of cancerous cells. Information about the expression of EphB4 in 
a tumour could also provide prognostic information, based on the observation that high EphB4 
expression in some tumours is associated with a higher potential for metastasis and fatal 
disease.
17
 In addition to its role in disease, EphB4 plays several crucial functions related to 
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normal development and physiology, including angiogenesis and neuronal development. Any 
EphB4 specific modulators could be useful for examining these processes in a research setting. 
 In previous work, Hierarchical Virtual Ligand Screening (HierVLS) was used to screen a 
model of the EphB4 kinase domain against 1,153 small molecules and identify three potential 
ligands.
18
 HierVLS is a high-throughput technique that is used to dock different conformations of 
potential ligands into binding sites of a known protein structure, and then score them using a 
force-field based approach.
19
 Several X-ray crystal structures of the EphB4 kinase domain are 
available from the Protein Data Bank, and 2VWZ was used as the target structure for virtual 
screening. In this investigation, we sought to experimentally characterize the effect of three 
selected hits, aminopterin, dihydrofolic acid (DHF), and N-(2,4)-dinitrophenyl-L-arginine (DNP-
L-Arg) on EphB4 kinase activity using two in vitro kinase assays: a homogenous time-resolved 
FRET assay for kinase activity as well as a spectrophotometric coupled kinase assay. Here we 
describe the results of these assays and discuss potential challenges and future research 
directions.  
6.2. MATERIALS AND METHODS 
6.2.1. Computational screening of EphB4 kinase 
Virtual modelling and screening of EphB4 kinase are described in full detail in a previous 
work.
18
 EphB4 kinase structure PDB:2VWZ was used for modeling. Missing side chains and 
atoms were added into the protein structure using YASARA software.
20
 A missing loop segment 





) were removed from the structure. The EphB4 model was energy 
minimized using the Dreiding force field prior to docking.
21
 A database of 2,153 compounds 
(obtained from PubChem) containing a primary amine functional group was prepared for 
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docking by removing counter-ions and performing an energy minimization using the MMFF94x 
force field in MOE.
22-23
 This database was prepared in collaboration with John Wigg, and has 
been described in more detail in his Master’s thesis document. The database was screened 
against the target structure using HierVLS, and three hit compounds were selected for testing 
based on raw predicted binding score and commercial availability. 
6.2.2. Materials 
All reagents were obtained from Sigma Aldrich, Inc unless otherwise noted. 
6.2.3. Homogenous time-resolved FRET assay (HTRF) 
Kinase activity was measured using a homogenous time-resolved fluorescence resonance energy 
transfer (HTRF) assay kit according to the manufacturer’s recommendations (Millipore, Inc. 
Cat#17-10015).
24
 The basic scheme for this assay is shown in Figure 6.2.3-1. During the 
reaction, EphB4 phosphorylates a commercial biotinylated peptide substrate. A europium-
chelated (Eu) anti-phosphotyrosine (PTyr) antibody binds to phosphorylated tyrosine residues 
produced by EphB4 kinase activity. Streptavidin-allophycocyanin complex (Strep-APC) is added 
after the reaction. Strep-APC will form a strong non-covalent bond with biotin on the peptide 
substrate. When the substrate has been phosphorylated (from EphB4 kinase activity), the Eu-
antibody will bind to PTyr. This will bring the fluorescence resonance energy transfer donor (Eu) 
into close enough proximity to the acceptor (APC) for the energy transfer (and fluorescence from 
APC) to occur. Eu, when excited, will fluoresce at 680nm, while APC, when acting as an 
acceptor, will fluoresce at 620nm. The “HTRF ratio”, a relative measure of fluorescence at the 





Figure 6.2.3-1 – A basic flowchart indicating the steps associated with kinase reaction detection 
– EphB4 kinase activity phosphorylates Tyr on biotinylated peptide substrate followed by 
detection using an Eu-chelated anti-PTyr antibody (binding to PTyr) and Streptavidin-APC 
(binding to biotin) and subsequent FRET to produce signal. (Figure reproduced courtesy of EMD 
Millipore from the user guide for Cat#17-10015).
24
 
Active recombinant EphB4 kinase (a.a. 563-987) was obtained from GenWay Biotech, 
Inc. 1X KinEASE (Millipore, Inc) buffer was prepared following manufacturer’s instructions 
with components at the following reaction concentrations: stock KinEASE buffer (Part# 
CS206508) – 1X MnCl2 (Part# CS206510,1 mM), MgCl2 (Part# CS206511) – 5mM, sodium 
orthovanadate (Part# CS206465) – 0.1mM, and dithiothreitol (DTT) (Part# 90499) – 1mM. 1X 
KinEASE buffer was used to dilute reaction components from stock unless otherwise specified. 
Kinase reactions were carried out for 1 hour with light shaking at 37°C in a 96 well black Costar 
half-area microplate at a 25μL reaction volume with the following reagent concentrations:EphB4 
Kinase– 0.8ng/μL (20ng/well), ATP (Part# CS206509) - 100μM, biotinylated TK2 Peptide 
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(Part# CS206505) – 1μM. Detection reagent mix was prepared in detection buffer (Part# 
CS206478) and added following the kinase reaction, with the final concentrations (in a total well 
volume of 50μL) as follows: Eu-4G10 anti-phosphotyrosine antibody (Part# CS206507) – 
0.175μg/mL and streptavidin-APC (Part# CS206501) – 0.0625μM. Note that the relative 
detection concentrations of biotin/streptavidin-APC have a fixed 1:8 ratio (biotinylated TK2 
peptide –0.5μM, streptavidin-APC –0.0625μM). Fixing the biotin/Strep-APC ratio is necessary 
to ensure consistent signal if the concentration of biotinylated peptide changes. 
Optimal EphB4 kinase concentration was determined to be 20ng/well (16nM) by 
performing a standard curve according to the manufacturer’s suggested protocol (supplementary 
material). 1mM stock ligand solutions were prepared for aminopterin, DNP-L-Arg (Cat# 
D8129), and dihydrofolic acid (DHF) (Cat# D7006) in 20%, 20%, and 0% DMSO (respectively) 
in water for a maximum reaction DMSO concentration of 2%. A 500μM staurosporine (kinase 
inhibitor control) stock was prepared from the 2.5mM solution provided with the kit (Part# 
CS201728) for a maximum DMSO reaction concentration of 3.3%. Two-fold serial dilutions of 
the test compound working solutions were prepared in 1X KinEASE buffer for reaction 
concentrations of 100, 50, 25, 12.5, and 6.25μM. Kinase only (kinase with 3% DMSO in absence 
of test-compound), buffer only, kinase negative, and Eu-4G10 only control wells were included 
according to the manufacturer’s recommendation. Each reaction was performed in duplicate. 
A dose-response curve for biotinylated phosphotyrosine peptide standard was also 
prepared in tandem with the compound testing assay on the same plate. Lyophilized biotinylated 
phosphotyrosine standard (Part# CS206507) was dissolved in 109.6μL of distilled water for a 
50μM working solution. A phosphotyrosine peptide standard solution was then prepared using 
4.8μL of the 50μM stock, combined with 30μL of streptavidin-APC (stock) and 85.2μL of 
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detection buffer (stock). Plate was read 1 hour after detection reagent addition with the following 
read parameters: excitation - 360/40 nm, emission - 680-30 nm and 620-40nm, counting delay - 
50μsec, integration time - 400μsec. HTRF ratios were calculated according to: 
Equation 6.2.3-1 – HTRF ratio calculation based on emission readings at 680nm and 620nm. 
        
             
             
         
Curve fitting was performed using PRISM software using the non-linear sigmoidal dose-
response curve (variable slope) or linear regression unless otherwise noted
25
. Hanes-Woolf plots 
were used to roughly approximate kinetic parameters according to the following relationships: 
Equation 6.2.3-2 – The relationship between the slope of the Hanes-Woolf regression (m) and 
Vmax. 
         
Equation 6.2.3-3 – The relationship between the x-intercept of the Hanes-Woolf regression and 
the Michaelis-Menten constant (Km). 
                 
6.2.4. Spectrophotometric coupled kinase assay 
The EphB4 kinase reaction was coupled to the enzymatic oxidation of NADH via 
pyruvate kinase (PK) and lactate dehydrogenase (LDH) enzymes in the presence of 




Figure 6.2.4-1 – A spectrophotometric coupled assay was used to measure kinase activity. ADP 
produced by the kinase reaction would be measured through conversion of phosphoenolpyruvate 
(PEP) to pyruvate with pyruvate kinase (PK) followed by action by lactate dehydrogenase 
(LDH) to produce lactate through the oxidation of NADH. NADH absorbs at 340nm allowing 
the decrease in absorbance to be used to approximate ADP production by EphB4 kinase. ATP is 
regenerated during this process. Figure generated using ChemDraw Software (Perkin Elmer). 
This coupling scheme has been employed in numerous kinetic studies of kinases
26-33
, including 
tyrosine kinases such as EGFR
28, 33
 and EphA4 (an EphB4 relative)
27, 32
. Enzyme, substrate, and 
cofactor concentrations were selected according to ranges found in the literature.
27, 32
 
Recombinant EphB4 kinase (Cat# SRP0347) was obtained from Sigma Aldrich. Reactions were 
carried out in 60mM HEPES pH 7.5 buffer containing 20mM MgCl2, 10mM MnCl2 and 0.1mM 
dithiothreitol (DTT). Coupling reaction component concentrations were as follows (unless 
otherwise stated): PEP (Cat# P7127) – 1mM, PK/LDH (Cat# P0294) – PK – 10-20U & LDH – 
20-30U, NADH (Cat# N0786) – 0.3mM). Preliminary reactions were carried out at a fixed 
EphB4 concentration of 0.05µM with varying Poly-Glu-Tyr (4:1) substrate (Cat# P0275) 
concentrations and/or varying ATP (Cat# A3377) concentrations. Reaction ATP concentration 
was otherwise 2mM. NADH standard curves (5 points between 1.5mM – 0.09375mM) were 
prepared on each plate. Several concentrations of ADP (Cat# A5285 ) were tested with the 
coupling system alone (no EphB4), and in the presence of test compound (DNP-L-Arg) to 
evaluate baseline NADH turnover (alone and in the presence of test compound). To test 
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compounds for their effect on EphB4 activity, varying DNP-L-Arg (Cat# D8129) and 
staurosporine (Millipore Cat# CS201728) reaction concentrations were used (200, 100, 50, 25, 
12.5, 6.25µM for DNP-L-Arg and 100, 50, 25, 12.5, 6.25µM for staurosporine). Separate control 
reactions containing vehicle control (3% DMSO) instead of test compound with and without 
EphB4 were performed. Test compound reactions and associated controls were run with an 
EphB4 kinase concentration of 0.025µM, Poly-Glu-Tyr concentration of 122µM and an ATP 
concentration of 2mM, in triplicate. All reaction volumes were 100µL in a 96 well clear bottom 
microplate. Reactions were initiated with the addition of EphB4 kinase and proceeded at room 
temperature. Absorbance at 340nm was read at minimum possible time intervals (2-30seconds) 
using a Synergy 4 microplate reader. Reactions were monitored for 20-45 minutes depending on 
whether a steady state appeared to be reached (whether well values continued to change 
significantly over time). Reaction velocities (Δabs340nm/s) were determined by selecting a time 
threshold beyond which reactions exhibited a “steady-state” of absorption decrease over time 
(generally between 500-1700s from reaction initiation) and performing a linear regression 
(where x>threshold). For subsequent analysis, reaction wells with a linear regression coefficient 
(R
2
) poorer than 0.65 were excluded to a maximum of 1 out of 3 replicates.  
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6.3. RESULTS AND DISCUSSION 
6.3.1. Compounds selected for experimental testing 
Based on the virtual screening of EphB4 and preliminary in vitro testing in a previous 
investigation
18
, three compounds were selected for further experimental testing to determine 
whether they could affect EphB4 activity: N-(2,4)-dinitrophenyl-L-arginine (DNP-L-Arg), 
dihydrofolic acid, and aminopterin (Figure 6.3.1-1). 
 
Figure 6.3.1-1 – Three hit compounds were selected for in vitro testing: N-(2,4)-dinitrophenyl-
L-arginine (DNP-L-Arg), dihydrofolic acid, and aminopterin. 
6.3.2. Homogenous time-resolved FRET assay (HTRF) 
A kit-based homogenous time-resolved fluorescence assay (HTRF) was used to test all 
three compounds as well as staurosporine, a known general kinase inhibitor used as a positive 
control. The dose-response curve for staurosporine against EphB4 obtained using the HTRF 
assay is shown in Figure 6.3.2-1. There is evidence of an inhibitory effect, and non-linear curve 
fitting using PRISM yielded an IC50 estimate of 18.59μM (95% confidence interval of 17.22-
20.07μM). The dose-response of staurosporine is also shown in Figure 6.3.2-1 relative to the 
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other compounds tested. At each concentration tested, DHF and aminopterin showed little 
change relative to control (EphB4 alone), and did not exhibit a clear dose-dependency. DNP-L-
Arg was the only other compound that appeared to have some evidence of effect – at higher 
DNP-L-Arg concentrations, product formation (evidenced by HTRF ratio) was possibly elevated, 
and appeared to decrease with decreasing concentration of DNP-L-Arg (Figure 6.3.2-2).  
 
Figure 6.3.2-1 – The HTRF assay dose-response curve for staurosporine against EphB4 (16nM) 
with an IC50 estimate 18.59μM (95% confidence interval of 17.22-20.07μM). 
The dose response curve for DNP-L-Arg is shown in Figure 6.3.2-3. The EC50 estimate 
from non-linear regression was 26.78μM however a confidence interval could not be 
approximated given the high level of standard deviation between replicates and poor curve fit. 
Though there was significant signal variation between replicates, DNP-L-Arg appeared to exhibit 
an effect in the opposite direction to that of the known kinase inhibitor, staurosporine. This was 
unexpected, as we anticipated either an inhibitory effect or no effect (such as was the case with 
the other two compounds tested). Due to the limited ability for this assay format to show 
significant increase in activity relative to baseline, and overall poor repeatability, we decided to 




Figure 6.3.2-2 – HTRF ratios are compared for the compounds tested at each concentration. 
Error bars represent standard deviation between duplicates. 
 
Figure 6.3.2-3 – The HTRF assay dose-response curve for DNP-L-Arg against EphB4 (16nM) 
indicating a possible shift in effect direction relative to staurosporine, a known kinase inhibitor. 
6.3.3. Possible mechanism of DNP-L-Arg interaction based on docked structure 
Initial screening had aimed primarily to identify kinase inhibitors. As mentioned in the 
introduction, many studies in the literature examine kinase inhibition for its therapeutic 
relevance, and no alternative types of small modulators have been described for the EphB4 
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kinase domain. Based on the results from the HTRF assay that were possibly counter indicative 
of inhibition, we revisited the computational docked structure and proposed alternative 
mechanisms of action. Based on a literature review of tyrosine kinase modulation, we suggest 
some plausible mechanisms through which a small molecule such as DNP-L-Arg could activate 
EphB4 kinase. 
The kinase domain contains one N-terminal and one C-terminal lobe. The N-terminal 
lobe generally consists of a 5-stranded β sheet that adopts a twisted structure (strands denoted by 
β1 to β5), along with one α-helix (αC). The juxtamembrane segment (JMS) is a short 
(approximate 10 amino-acid) sequence near the N-terminus of kinase domains. Nomenclature 
adopted here follows the one previously used to describe the EphB2 structure (PDB: 1JPA).
34
 
The larger C-terminal lobe consists mainly of helices and is connected to the N-terminal lobe by  
a short “hinge” linker, which forms a flexible inter-lobe cleft. Structural studies of insulin 
receptor kinase (IRK), EphB2, and EphA4 have described the mechanism of kinase activation 
and catalysis in detail.
28, 32, 34-35
 Several regions within the β-sheet and connecting loops are 
responsible for coordinating ATP in the active site, while the C-terminal lobe coordinates the 
peptide substrate. A flexible activation (A-) loop structure spans the cleft between the two lobes, 
and plays a key role in regulating activity. Several conserved tyrosine residues in the JMS and A-
loop are sites for trans- and auto-phosphorylation. The phosphorylation of these tyrosine residues 
can activate the kinase by promoting a conformation favorable for catalysis. In an autoinhibited 
kinase, the dephosphorylated A-loop acts as a pseudo-substrate inhibitor, blocking access of the 
peptide substrate to its binding site. Upon phosphorylation of A-loop tyrosines, however, the A-
loop changes conformation and restores substrate access to the active site. The EphB2 crystal 
structure (PDB: 1JPA) demonstrates that when autoinhibited, the JMS associates closely with the 
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N-terminal lobe, altering the position of catalytic residues and preventing an “active” 
conformation likely by restricting inter-lobe flexibility. This auto/trans phosphorylation 
activation mechanism is supported by studies on EphB2, EphA4 and insulin-like growth factor 
receptor.
27, 34, 36
 Li et al postulate that the cleft anchoring autoinhibitory tyrosine residues could 
also be targeted by small molecules which would displace tyrosine and activate the receptor.
36
  
Several studies also suggest that it is possible to activate tyrosine kinases using small 
molecules, by affecting one of the mechanisms described above. In 2001, DMAQ-B1, a small 
molecule microbial isolate, was found to activate IRK in an insulin-independent manner.
37
 It was 
proposed that the autoinhibitory conformation of IRK is altered upon DMAQ-B1 binding. 
Protease sensitivity experiments suggested that DMAQ-B1 altered the conformation of IRK in 
regions proximal to the ATP-binding site which would be consistent with mechanisms described. 
The same year, TLK16998, another small-molecule IRK activator, was found to sensitize cells to 
insulin, acting through the kinase domain.
38
 While these compounds’ activities have been 
characterized in vitro and in vivo, the exact activation mechanism remains unclear. 
These previous investigations highlighted the potential for the development of allosteric 
tyrosine kinase activators. Due to their critical and somewhat ubiquitous role in cell signaling, 
and development, receptor tyrosine kinases have been extensively studied, largely in the context 
of therapeutic inhibition. Though the inhibition of some specific tyrosine kinase-mediated 
signaling pathways seems to be desirable in the context of anti-cancer drug development, the 
complex roles of Ephs and other tyrosine kinases would likely be better understood if these 
activation mechanisms were better characterized. The development of alternative (non-
inhibitory) modulators could provide valuable insight for research. To date, there are no specific 
small-molecule allosteric activators of the Eph receptor family that have been reported. The high 
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degree of structural and functional conservation between these families of enzymes makes it 
reasonable to expect that mechanisms exploited for drug-development in Ephs would also be 
useful in the context of related proteins. With this in mind, we examined docked structures for 
DNP-L-Arg compared to structures containing docked or crystallized active site inhibitors.  
Figure 6.3.3-1 displays the superposed orientation of AMP-PNP(green), an ATP-
competitive inhibitor co-crystallized with EphB2
34
, along with the orientation of a known EphB4 
inhibitor, 7X6 (orange)(which has also been previously co-crystallized with EphB4
8
) in the 
orientation that was predicted using our docking protocol, as well as the docked structure for 
DNP-L-Arg (magenta). Note that both AMP-PNP and 7X6 have overlapping regions that 
correspond to the ATP binding site. The predicted binding site for DNP-L-Arg, however, does 
not overlap with the ATP binding location. The predicted orientation of DNP-L-Arg is adjacent 
to the ATP binding site, associating with the N-terminal domain and, more generally, the inter-
lobe cleft region. Two effects could arise from this binding location: because the inter-lobe cleft 
plays a role in substrate binding, DNP-L-Arg could prevent activity by interfering with the 
interactions of this lobe and the peptide substrate, or by interfering with the accessibility of the 
ATP-binding site. DNP-L-Arg could also interfere with normal kinase autoinhibition, in which 
case its effect could be less predictable. It is reasonable to suggest that DNP-L-Arg could 
increase the favorability of a catalytically competent conformation, increasing the number of 
enzyme molecules participating in catalysis. Alternatively, affecting inter-lobe flexibility may 






Figure 6.3.3-1 – Left: Docked or crystal structure conformations for three ligands are shown for 
EphB4 kinase relative to the N- and C-terminal lobes. Right: AMP-PNP (adenine 
moiety)(PDB:1JPA) (green) and 7X6 (inhibitor)
8
 docked using our protocol (orange) occupy 
similar sites in the structure while DNP-L-Arg (magenta) is predicted to bind further from the 
active site. 
6.3.4. Spectrophotometric coupled kinase assay 
A spectrophotometric coupled assay, as described in the literature, was chosen due to its 
non-proprietary detection components (in order to facilitate future work), its kinetic format, and 
its previous use in examining allosteric activation mechanisms in other tyrosine kinases. To test 
the function of the coupling system, we incubated varying concentrations of ADP with the 
coupling system alone to ensure rapid turnover of large amounts of ADP (relative to what would 
likely be produced by EphB4 kinase). The coupling system performed as expected, with all of 
the observed decrease in absorbance at 340nm (Abs340) occurring within the first 10 seconds 
after the addition of lactate dehydrogenase and pyruvate kinase (PK and LDH). Though these 
reactions were monitored over time, because the turnover occurred rapidly, we used absorbance 
at 340nm after10s to signify overall response (Figure 6.3.4-1). It is clear from this preliminary 
experiment that even when completely saturated with ADP substrate, the coupling system is 
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capable of complete turnover in a very short (10s) time window, giving us confidence that it 
would be appropriately responsive for kinetic tests measuring EphB4 kinase activity.  
EphB4 kinase was tested alone (without inhibitor or test ligand) and a constant decrease 
in absorbance (corresponding to the coupled oxidation of NADH) was observed relative to a 
control where all components were included except for EphB4 kinase (Figure 6.3.4-2). An 
initial, very rapid, decrease in Abs340 was invariably observed in our tests whenever ATP and the 
coupling components were present (even in the absence of EphB4), and we suggest that this is 
likely due to small amounts of ADP present with the ATP, which are rapidly converted by the 
coupling system near the start of the reaction, and are unrelated to EphB4 kinase activity. 
Overall, regression coefficients for analyses of the linear regions of each reaction were high 
(>0.85). Some reactions exhibited a delay in apparent reaction initiation, such that few data 
points were captured in the linear region. This could perhaps be due to temperature variation or 
inconsistency in the timing of addition of reagents and measurement. A “lag phase” has been 
observed in other tyrosine kinase studies
27
, and could be shortened by pre-incubating the kinase 
with ATP prior reaction initiation to facilitate phosphorylation-mediated autoactivation. The 
overall steady-state rates observed ranged between 4-8 ΔAbs340/s/µmol EphB4, which are 
significantly higher than those observed by Binns et al using the same assay format for EphA4, 
who observed a maximum steady-state velocity of 2.12 ΔAbs340/s/µmol of kinase.
27
 This 
difference may be accounted for by the fact that a different Eph isoform, EphA4 was used. DNP-
L-Arg and staurosporine were both tested at multiple concentrations (6 and 5 respectively) 
between 200µM and 6.25µM. Selected reactions for DNP-L-Arg and staurosporine at 100µM are 




Figure 6.3.4-1 - Abs340 at 10s with varying initial concentrations of ADP with the coupling 
system alone. The Abs340 of the starting assay concentration of NADH alone, and in the presence 
of all reaction components except for PK/LDH (No PK/LDH), as well as a buffer control, are 
shown for reference. 
It is difficult to clearly discern effects here given the high level of variability between 
assay replicates. In all cases except for at the 100µM concentration, staurosporine either 
exhibited no significant change, or some decrease in velocity relative to control. Testing at 
higher concentrations, with additional replicates could be used to determine whether the data at 
100µM was anomalous. DNP-L-Arg data is similarly ambiguous given the standard deviation 
between replicates. Relative reaction velocities for DNP-L-Arg and staurosporine wells are given 
in Figure 6.3.4-4. A Hanes-Woolf plot of [Compound]/V as a function of [Compound] is shown 
in Figure 6.3.4-5. 
 Regression parameters and associated constants are compiled in Table 6.3.4-1. R
2
 values 
are not given as they cannot be used as a reliable measure of the goodness of the fitting for 
Hanes-Woolf plots (as plotted variables are not independent). The x-intercept results in a 
negative Km determination for the peptide substrate. This could be a result of both the limited 
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number and range of concentrations tested as well as the limitations of linear approximations for 
kinetic analyses. Note that apparent Vmax values obtained in the presence of DNP-L-Arg and 
staurosporine differ. Given that staurosporine is known to be an ATP-competitive inhibitor, 
dissimilar Vmax values for DNP-L-Arg, staurosporine, and peptide could indicate different or 
mixed site of action. However, generally, definitive conclusions based on these data would be 
unwise. Future experimental work should aim to ensure optimization of reaction components and 
repeatability with this assay format. A better understanding of compound effects on EphB4 
would be possible if staurosporine and DNP-L-Arg were tested at multiple concentrations while 
varying substrate concentrations (ATP and peptide).  
 
Figure 6.3.4-2 – Spectrophotometric coupled kinase assay indicating decrease in absorbance at 




Figure 6.3.4-3 – The coupled assay data from two exemplary reaction wells with staurosporine 
and DNP-L-Arg each at 100µM with EphB4 (0.025µM). Linear regression was performed on 
time>1700s. 
 
Figure 6.3.4-4 – A comparison of individual reaction velocities (ΔAbs340/s/µmol EphB4) 





Figure 6.3.4-5 – A Hanes-Woolf plot is used to represent [Compound] (µM) as a function of 
[Compound] (µM)/V (ΔAbs340/s/µmol EphB4) using the coupling-assay. Reactions containing 
staurosporine, DNP-L-Arg, as well as a control reaction with varying peptide (polyGluTyr) 




Table 6.3.4-1 – Regression parameters obtained from the Hanes-Woolf plot with associated 
constants for DNP-L-Arg, staurosporine, and varied concentrations of peptide substrate (no 
inhibitor). Note that reaction velocity is expressed as ΔAbs340/s/µmol EphB4. 
Compound Slope (m) Y-Intercept (b) X-Intercept (x) Km (µM) Vmax 
DNP-L-Arg -0.162 -0.0235 -0.145 0.145 -6.18 
Staurosporine -0.120 -2.34 -19.5 19.5 -8.34 
Peptide Substrate -0.426 5.00 11.8 -11.8 -2.35 
 
6.4. CONCLUSIONS 
Through high-throughput virtual screening we identified three potential candidates for 
testing as EphB4 kinase ligands. One in vitro assay identified DNP-L-Arg as the most promising 
candidate for affecting EphB4 kinase activity; however the observed response was that of 
possible activation rather than inhibition. A second spectrophotometric coupled assay gave 
inconclusive results. A review of the literature supports the hypothesis that a small molecule 
such as DNP-L-Arg could activate kinase activity through interfering with normal autoinhibitory 
mechanisms. The docked structure of DNP-L-Arg further suggests that if DNP-L-Arg is 
affecting EphB4 activity, it may be doing so through a different mechanism than by competing 
for the active site, and the possible effects could include activation or inhibition.  
The spectrophotometric assay format has the advantages of being rapid, flexible, non-
proprietary (uses fairly ubiquitous detection components), and non-radioactive. While it has been 
used to characterize other, similar enzymes (such as EphA4), no examples of this assay being 
used with EphB4 have been published as of yet. The data obtained using this assay requires 
caution. For example, it is possible that the addition of untested components could affect the 
coupling system. We tested this in a preliminary experiment to ensure that turnover remained 
rapid in the presence of our test compounds, however this would have to be repeated if different 
compounds or conditions were to be tested. 
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The relative uncertainty surrounding the mechanisms by which kinases may be activated 
or regulated underscores the importance of continuing this research. Additional experimentation 
could be used to better characterize the effect of DNP-L-Arg on EphB4 kinase activity with 
varying compound and substrate concentrations. It would be valuable to compare this with the 
action of known small molecule kinase inhibitors and activation mechanisms using the same 
assay format. 
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The focus of these projects was the utilization of computational tools as an integral part 
of the drug design process. Using virtual ligand screening we identified a series of probe 
candidates for CAIX that, if confirmed on experimental testing, could be further developed into 
agents for diagnosis or response to therapy either in vitro or in vivo. Virtual ligand screening was 
also used as a proof-of-concept tool to validate an approach that could create computational 
structures of ligands bound to fluorescent dye moieties, which would be useful for future 
molecular docking studies against any number of potential targets. Lastly, additional 
experimental characterization was performed on an EphB4 kinase ligand, DNP-L-Arg, which 
was previously identified through virtual ligand screening. These results indicate that DNP-L-
Arg may act on EphB4 through an activation mechanism, which is supported by the literature 
and can be explained by software-assisted visualizations of the predicted binding site. The 
number of techniques and applications explored throughout these projects highlights the 
versatility of computational methods in these fields and exemplifies the ways in which these 
techniques can be integrated into different areas of multidisciplinary research .A major 
advantage of computational techniques is the ability to explore molecular systems theoretically, 
in a manner that is less costly, prior to undertaking significant experimental work. However, 
there are always limitations in the ability of simulations to accurately predict conformations and 
interactions. In each of the projects described here, additional experimental work will be required 
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